WO2008010953A2

WO2008010953A2 - Pyridinone diketo acids: inhibitors of hiv replication in combination therapy

Info

Publication number: WO2008010953A2
Application number: PCT/US2007/015981
Authority: WO
Inventors: Vasu Nair; Byung I. Seo; Vinod R. Uchil; Guochen Chi
Original assignee: University Of Georgia Research Foundation, Inc.
Priority date: 2006-07-19
Filing date: 2007-07-13
Publication date: 2008-01-24
Also published as: MX2009000661A; WO2008010953A3; CA2657034A1; US20100092427A1; US20080020010A1; EP2046328A2; EP2046328A4; AU2007275805A1; US7888375B2; JP2009543865A

Abstract

A new class of diketo acids constructed on pyridinone scaffolds, designed as inhibitors of HTV replication through inhibition of HIV integrase, is described. These compounds are useful in the prevention or treatment of infection by HIV and in the treatment of AIDS and ARC, either as the compounds, or as pharmaceutically acceptable salts, with pharmaceutically acceptable carriers, used alone or in combination with antivirals, immunomodulators, antibiotics, vaccines, and other therapeutic agents, especially other anti-HIV compounds (including other anti-HIV integrase agents), which can be used to create combination anti-HIV cocktails. Methods of treating AIDS and ARC and methods of treating or preventing infection by HIV are also described. Compounds of the present application include those of formula I and include tautomers, regioisomers, geometric isomers, and pharmaceutically acceptable salts thereof, wherein the pyridinone scaffold and R groups are as otherwise defined in the specification. These are combined, with any number of typical other anti-HIV agents (including other integrase-based anti-HIV agents) and other combination therapeutic agents described herein, to provide an effective treatment modality for HIV infections, including AIDS and ARC.

Description

PYRIDINONE DIKETO ACIDS: INHIBITORS OF fflV REPLICATION

IN COMBINATION THERAPY

FIELD OF THE INVENTION The present invention relates to the field of antiviral therapy, in particular the treatment of HIV infections in humans, preferably in combination therapy.

RELATEDAPPLICATIONS AND GRANT SUPPORT

This application claims the benefit of priority of provisional application number

US60/831.990, filed July 19, 2006, provisional application number US60/920,196, filed March 27, 2007, both entitled, "Pyridinone Diketo Acids: Inhibitors of HIV Replication", and provisional application number 60/920,197, filed March 27, 2007, entitled, "Pyrinone Diketo Acids: Inhibitors of HIV Replication in Combination Therapy", each of which applications is incorporated by reference in its entirety herein.

The work leading to the instant patent application was supported in part by a grant from the National Institutes of Health, award number A143181. Consequently, the United States government retains certain rights in the invention.

BACKGROUND OF THE INVENTION

The human immunodeficiency virus, HIV, encodes three key viral enzymes through its pol gene and these enzymes are critical for the replication of this virus [Fauci, Science, 239, 617-622 (1988); Katz & Skalka, Annu. Rev. Biochem., 63, 133-173 (1994); Frankel, Annu. Rev. Biochem., 67, 1-25 (1998)]. For this reason, these enzymes of the pol gene have been targeted as potential sites of attack in the development of HIV antiviral chemotherapeutic agents [De Clercq, J. Med. Chem. 38, 2491-2517 (1995); Clin. Microbiol. Rev., 10, 674-693 (1997); De Clercq, Nature Reviews: Drug Discovery, 11, 13-25 (2002); De Clercq, J. Med Chem. 48, 1297-1313 (2005)]. Drug discovery involving two of these enzymes, HIV reverse transcriptase (RT) and HIV protease (PR), and subsequent clinical applications of some of these therapeutic agents in combination therapy for the treatment of acquired immunodeficiency syndrome (AIDS) and AIDS related complex (ARC) in HAART (highly-active antiretroviral therapy) have suggested that this methodology of targeting key viral enzymes represents a useful approach in antiviral chemotherapy [Johnson & Gerber, in "Advances in Internal Medicine," vol. 44. Mosby: St. Louis, 1-40 (2000); De Clercq, Nature Reviews: Drug Discovery, 11, 13-25 (2002); Miller & Hazuda, Current Opinion in Microbiology, 4, 535-539 (2001); Asante-Appiah & Skalka, Adv. Virus Res., 52, 351-369 (1999); Nair, in "Recent Advances in Nucleosides: Chemistry and Chemotherapy," Elsevier Science: Netherlands, 149-166 (2002); DeClercq, Intl. J. Biochem. Cell Biol 36, 1800-1822 (2004)]. While HIV RT and HIV PR have been extensively studied with respect to therapeutics, the third enzyme of the pol gene, HIV integrase, has received much less consideration [Miller & Hazuda, Current Opinion in Microbiology, 4, 535-539 (2001); Nair, Rev. Med. Virol., 12, 179-193 (2002); Nair, Current Pharmaceutical Design, 9, 2553-2565 (2003); Pommier, et ah, Nature Rev. Drug Discovery 4, 236-248 (2005); Nair, Frontiers in Med. Chem. 2, 3-20 (2005)].

At present there are no drugs in clinical use for HIV/AIDS where the mechanism of action is inhibition of HIV integrase. HIV-I integrase is a protein of 32 kDa encoded at the 3'-end of the pol gene [Asante-Appiah & Skalka, Adv. Virus Res., 52, 351-369 (1999); Esposito & Craigie, Adv. Virus Res., 52, 319-333 (1999)]. It is involved in the integration of HIV DNA into the host cell chromosome. Because integrase has no human counterpart and because it plays the significant role of completing the invasion of the human cell cell by HIV₃ it is an attractive target for the discovery of inhibitors of therapeutic potential. Incorporation of HIV DNA into host chromosomal DNA in the cell nucleus catalyzed by integrase apparently occurs by a specifically defined sequence of 3 '-processing or tailoring and strand transfer/ integration reactions [Asante-Appiah & Skalka, Adv. Virus Res., 52, 351- 369 (1999); Esposito & Craigie Adv. Virus Res., 52, 319-333 (1999)]. Prior to the initiation of the integration process, there is assembly of viral DNA, previously produced by reverse transcription, on the integrase. HIV integrase recognizes specific sequences in the LTRs of viral DNA. Following assembly of viral DNA on integrase, the processing of viral DNA occurs where there is site specific endonuclease activity and two nucleotides are cleaved off from each 3'-end of the double helical viral DNA to produce the tailored viral DNA recessed by two nucleotides and bearing a terminal CAOH-3'. For this initial 3 '-processing step, integrase apparently activates the phosphodiester bond towards cleavage. The recessed viral DNA thus produced is joined in the next step to host cell DNA in the nucleus through a trans- esterification reaction. In this step, integrase positions the 3'-OH end of the viral DNA for micleophilic attack on the phosphodiester bond in the host DNA. In the subsequent step, there is cleavage of 4-6 bp in host DNA and the coupling involves the joining of processed CAOH-3' viral DNA ends to the 5'-phosphate ends of the host DNA. Finally, there is repair of the resulting gapped intermediate mediated by host cell enzymes, although a role, here for the integrase is also possible. A variety of compounds are inhibitors of HTV integrase but some of these compounds are non-specific inhibitors of the enzyme while evidence suggests that others may possess some specificity. The various classes include nucleotides, oligonucleotides, dinucleotides, and miscellaneous small molecules including heterocyclic systems, natural products, diketo acids, sulfones and others [Nair, Rev. Med. Virol., 12, 179-193 (2002); Nair, Current Pharmaceutical Design, 9, 2553-2565 (2003); Chi and Nair, Bioorg. Med. Chem. Lett. 14, 4815-4817 (2004); Nair and coworkers, J. Am. Chem. Soc, 122, 5671-5677 (2000)].

The class of previously studied compounds that are most directly relevant to this patent are diketo acids with aryl or heteroaryl substitutions. Some of these compounds are inhibitors of HIV integrase, but most commonly of only the strand transfer step. The integrase inhibition data have been reported in several scientific publications [Wai, et al., "4- Aryl-2,4-dioxobutanoic acid inhibitors of HIV-I integrase and viral replication in cells," J. Med. Chem. 43, 4923-4926 (2000); Pais, G. C. G., et al., "Structure activity of 3-aryl-l,3- diketo-containing compounds as HIV-I integrase inhibitors," J. Med. Chem. 45, 3184-3194 (2002); Marchand, C, et al., "Structural determinants for HIV-I integrase inhibition by β- diketo acids," J. Biol. Chem. 277, 12596-12603 (2002); Sechi, M., et al, "Design and synthesis of novel indole beta-diketo acid derivatives as HIV-I integrase inhibitors," J. Med. Chem. 47, 5298-5310 (2004); Zhang, et al., "Azido-containing aryl β-keto acid HIV-I integrase inhibitors," Bioorg. Med. Chem. Lett. 13, 1215-1219 (2003), Nair, et al., "HIV integrase inhibitors with nucleobase scaffolds: discovery of a highly potent anti-HIV agent," J. Med. Chem. 49, 445-447 (2006); Nair, et al., "Conceptually novel HIV integrase inhibitors with nucleobase scaffolds: discovery of a highly potent anti-HIV agent," Antiviral Res. 70, A26 (2006); Sato, et al., "Novel HIV-I integrase inhibitors derived from quinolone antibiotics," J. Med. Chem. 49, 1506-1508 (2006); Nair et al., "Beta-diketo acids with purine nucleobase scaffolds: novel selective inhibitors of the strand transfer step of HIV integrase," Bioorg. Med. Chem. Lett. 16, 1920-1923 (2006), Chi et al., "A novel diketo phosphonic acid that exhibits specific, strand-transfer inhibition of HTV integrase and anti-HIV activity," Bioorg. Med. Chem. Lett. 17, 1266-1269 (2007)]. Other publications in the area are of peripheral relationship to this patent application. The mechanism of inhibition of HIV integrase by diketo acids may be the result of interaction of the functional groups on these compounds with metal ions in the active site of integrase, resulting in a functional sequestration of these critical metal cofactors [ Grobler, J. A., et al, Proc. Natl. Acad. ScL U.S.A. 99, 6661-6666 (2002)].

Related patents to this application are: Selnick, H. G. et al, (Merck & Co. Inc.), "Preparation of nitrogen-containing 4-heteroaryl-2,4-dioxobutyric acids useful as HIV integrase inhibitors," WO 9962513; Young, S. D., et al, (Merck & Co. Inc.), "Preparation of aromatic and heteroaromatic 4-aryl-2,4-dioxobutyric acid derivatives useful as HIV integrase inhibitors," WO 9962897; Fujishita, T., et al., Yoshinaga, T., et al. (Shionogi & Co. Ltd.), "Preparation of aromatic heterocycle compounds having HIV integrase inhibiting activities," WO 0039086; Akihiko, S., (Shionogi & Co. Ltd.), "Medicinal compositions containing propenone derivatives," WO 0196329; Payne, L. S., et al, (Merck & Co. Inc.; Tularik, Inc.), "Preparation of l,3-diaryl-l.,3-propanediones as HIV integrase inhibitors," WO 0100578; Egbertson, M., et al, (Merck & Co. Ltd.), "HIV integrase inhibitors," WO 9962520. Some of the patents cited above are closely related. However, none of the patents or publications describe the class of compounds according to the present invention. Other patents of peripheral relationship to this invention are: Anthony, et al, (Merck & Co. Inc.), "Aza and polyaza-napthalenyl-carboxamides useful as HIV integrase inhibitors," WO 02/30426; Sato, et al., (Japan Tobacco Inc.), "Preparation of 4-oxoquinoline derivatives as HIV integrase inhibitors," WO 2004046115; Sato, et al, (Japan Tobacco Inc.), "Novel 4-oxoquinoline compounds and use thereof as HIV integrase inhibitors," WO 2005113509; Crescenzi, et al, (Instituto Di Richerche Di Biologia Molecolare P. Angeletti SPA) "Preparation of N- substituted hydroxypyrimidinone carboxamide inhibitors of HIV integrase," WO 2003035077; Belyk, et al, (Merck & Co. Inc., Instituto Di Richerche Di Biologia Molecolare P. Angeletti SPA), "Preparation of N-(4-fluorobenzyl)-5-hydroxy-l-methyl-2-(l-methyl-l- {[(5-memyl-l,3,4-oxadiazol-2-yI)carbonyl]amino}emyl)-6-oxo-l,6-dihydropyrirnidine-4- carboxamide potassium salts as HIV integrase inhibitors," WO 2006060712; Sato, et al, (Japan Tobacco Inc.), "Preparation of quinolizinone compounds as HIV integrase inhibitors," WO 2006033422; Yoshida, H., et al, (Shionogi & Co. Ltd.), "Preparation of carbamoyl- pyridinone derivative having HIV integrase inhibitory activity," WO 2006030807; Dress, et al, (Pfizer, Inc.), "Preparation of N-hydroxy pyrrolopyridinecarboxarnides as inhibitors of HIV integrase," WO 2006027694; Naidu, et al, (Bristol-Myers Squibb Co.), "HIV integrase inhibitors," US 2005/0261322; Naidu, et al, (Bristol-Myers Squibb Co.), "Bicyclic heterocycles as HIV integrase inhibitors," US 2005/0267105; Naidu, et al., (Bristol-Myers Squibb Co.), "Bicyclic heterocycles as HIV integrase inhibitors," US 2006/0199956. While some of the patents cited above are more related than others, none of the patents or publications describe the class of compounds according to the present invention.

The class of compounds described by us in this invention are inhibitors of HIV-I integrase and also possess in vitro anti-HIV activity. An example of the anti-HIV data in

PBMC for the clinical isolate, HIV_NL4-₃, in PBMC for one of our compounds, 4-(l,5- dibenzyl-l,2-dihydro-2-oxopyridin-3-yl)-2-hydroxy-4-oxobut-2-enoic acid, (8) and AZT in the same study is given below.

Compound 8 EC₉₅ 0.6I uM, CC₉₅ >200 μM, Therapeutic Index (TI) >330

AZT EC₉₅ 9.42 nM, CC₉₅ > 1 μM, Therapeutic Index (TI) > 106

At pH 7.4, the half life (t_\n) of compound 8 is >41 hours. The Ua in pooled human liver microsome for compound 8 is >6 hours.

SUMMARY OF THE INVENTION A new class of diketo acids constructed on pyridinone scaffolds, and designed as inhibitors of HFV replication through inhibition of HIV integrase, is described. These compounds can be represented by the general formula I (and includes tautomers, regioisomers and geometric isomers thereof, as well as pharmaceutically acceptable salts thereof, where applicable), in which the moiety illustrated as a square is a molecular scaffold made up of a pyridinone derivative. These compounds have application, inter alia, in the prevention or treatment of infection by HIV and the treatment of AIDS and ARC, either as compounds, or as their pharmaceutically acceptable salts, with pharmaceutically acceptable carriers, used alone or in combination with antivirals, immunomodulators, antibiotics, vaccines, and other therapeutic agents, especially other anti-HIV compounds (including other anti-HIV integrase agents), which can be used to create combination anti-HIV cocktails. Methods of treating AIDS and ARC and methods of treating or preventing infection by HIV are also described. The present invention further relates in preferred aspects to the use of at least one of the above compounds in combination with at least one additional anti-HIV agent as otherwise described herein.

DETAILED DESCRIPTION OF THE INVENTION

The following terms shall be used throughout the specification to describe the present invention. Unless otherwise indicated, a term used to describe the present invention shall be given its ordinary meaning as understood by those skilled in the art.

The term "compound", as used herein, unless otherwise indicated, refers to any specific chemical compound disclosed herein and includes tautomers, regioisomers, geometric isomers, and where applicable, optical isomers thereof, as well as pharmaceutically acceptable salts thereof. Within its use in context, the term compound generally refers to a single compound, but also may include other compounds such as stereoisomers, regioisomers and/or optical isomers (including racemic mixtures) as well as specific enantiomers or enantiomerically enriched mixtures of disclosed compounds. The breadth of the term "compound" shall be construed within the context of the use of the term.

The term "patient" or "subject" is used throughout the specification to describe an animal, generally a mammal and preferably a human, to whom treatment, including prophylactic treatment, with the compositions according to the present invention is provided.

For treatment of those infections, conditions or disease states which are specific for a specific animal such as a human patient, the term patient refers to that specific animal.

The term "effective" is used herein, unless otherwise indicated, to describe an amount of a compound or composition or component which, in context, is used to produce or effect an intended result, whether that result relates inter alia to the treatment of a viral, microbial or other disease state, a disorder or condition associated with HIV, ARC or AIDS or alternatively, is used to produce another compound, agent or composition. This term subsumes all other effective amount or effective concentration terms which are otherwise described in the present application. The term "scaffold" is used throughout the specification to mean a pyridinone chemical structure containing at least four substituents at five substitutable positions on this scaffold, one of which is a ketoacid as otherwise defined herein and the other four of which R¹, R², R³ and R⁴ are as defined herein.

The term "heteroaryl" shall mean a 5 or 6-membered heteroaromatic ring containing 1 to 2 heteroatoms selected from oxygen, nitrogen and sulfur, which heteroaromatic ring is optionally substituted with from 1 to 3 substituents such as halogen, hydroxyl, C ₁.₃ alkyl, C ₁.₃ alkoxy and CF₃. The terms heteroaryl and "heteroaromatic ring" are used interchangeably herein.

The term "human immunodeficieincy virus" or "HIV" shall be used to describe human immunodeficiency viruses 1 and 2 (HIV-I and HIV-2).

The terms "ARC" and "AIDS" refer to syndromes of the immune system caused by the human immunodeficiency virus, which are characeterized by susceptibility to certain diseases and T cell counts which are depressed compared to normal counts. HIV progresses from Category 1 (Asymptomatic HIV Disease) to Category 2 (ARC), to Category 3 (AIDS), with the severity of the disease. A Category 1 HIV infection is characterized by the patient or subject being HIV positive, asymptomatic (no symptoms) and having never had fewer than 500 CD4 cells. If the patient has had any of the AIDS-defining diseases listed for categories 2 (ARC) or 3 (AIDS), then the patient is not in this category. If the patient's t-cell count has ever dropped below 500, that patient is considered either Category 2 (ARC) or Category 3 (AIDS).

A Category 2 (ARC) infection is characterized by the following criteria: The patient's T-cells have dropped below 500 but never below 200, and that patient has never had any Category 3 diseases (as set forth below) but have had at least one of the following defining illnesses —

0 Bacillary angiomatosis

0 Candidiasis, oropharyngeal (thrush)

0 Candidiasis, vulvovaginal; persistent, frequent, or poorly responsive to therapy

0 Cervical dysplasia (moderate or severe)/cervical carcinoma in situ o Constitutional symptoms, such as fever (38.5 C) or diarrhea lasting longer than 1 month o Hairy leukoplakia, oral o Herpes zoster (shingles), involving at least two distinct episodes or more than one dermatome o Idiopathic thrombocytopenic purpura o Listeriosis o Pelvic inflammatory disease, particularly if complicated by tubo-ovarian abscess o Peripheral neuropathy

According to the U.S. government, in Category 2 ARC, the immune system shows some signs of damage but it isn't life-threatening.

A Category 3 (AIDS) infection is characterized by the following criteria: your T-cells have dropped below 200 or you have had at least one of the following defining illnesses ~

o Candidiasis of bronchi, trachea, or lungs o Candidiasis, esophageal o Cervical cancer, invasive** o Coccidioidomycosis, disseminated or extrapulmonary o Cryptococcosis, extrapulmonary o Cryptosporidiosis, chronic intestinal (greater than 1 month's duration) o Cytomegalovirus disease (other than liver, spleen, or nodes) o Cytomegalovirus retinitis (with loss of vision) o Encephalopathy, HFV-related o Herpes simplex: chronic ulcer(s) (greater than 1 month's duration); or bronchitis, pneumonitis, or esophagitis o Histoplasmosis, disseminated or extrapulmonary o Isosporiasis, chronic intestinal (greater than 1 month's duration) o Kaposi's sarcoma o Lymphoma, Burkitt's (or equivalent term) o Lymphoma, immunoblastic (or equivalent term) o Lymphoma, primary, of brain o Mycobacterium avium complex or M. kansasii, disseminated or extrapulmonary o Mycobacterium tuberculosis, any site (pulmonary** or extrapulmonary) o Mycobacterium, other species or unidentified species, disseminated or extrapulmonary o Pneumocystis carinii pneumonia o Pneumonia, recurrent** o Progressive multifocal leukoencephalopathy o Salmonella septicemia, recurrent o Toxoplasmosis of brain o Wasting syndrome due to HIV

The term "coadministration" or "combination therapy" shall mean that at least two compounds or compositions are administered to the patient at the same time, such that effective amounts or concentrations of each of the two or more compounds may be found in the patient at a given point in time. Although compounds according to the present invention may be co-administered to a patient at the same time, the term embraces both administration of two or more agents at the same time or at different times, provided that effective concentrations of all coadministered compounds or compositions are found in the subject at a given time. In certain preferred aspects of the present invention, one or more of the diketo acid compounds described above, are coadministered in combination with at least one additional anti-HIV agent as otherwise described herein in a cocktail for the treatment of HIV infections. In particularly preferred aspects of the invention, the co-administration of compounds results in synergistic anti-HIV activity of the therapy.

The term "independently" is used herein to indicate that the variable, which is independently applied, varies independently from application to application.

The present invention is directed to compounds of the general molecular formula I, combinations thereof, or pharmaceutically acceptable salts thereof, in the inhibition of HIV integrase, the prevention or treatment of HIV infections and in the treatment of AIDS and ARC. Compounds of formula I are defined as follows:

including tautomers, regioisomers, and pharmaceutically acceptable salts thereof, wherein two representative pyridinone scaffolds and R groups are defined as:

diketo acids with the two pyridinone scaffolds shown;

R¹ and R² are independently: a) H, b) Ci.6 alkyl, c) C i .6 fluoroalky 1, d) Ci^ alkyl S(O)_nR, wherein n selected from 0-2, R is selected from Ci-₃ alkyl, phenyl and substituted phenyl with substituents selected from:

1) halogen,

2) hydroxy,

3) Ci_-3 alkyl, 4) Cu alkoxy,

5) CF₃, e) C₅-6 cycloalkyl with 1 to 3 substituents selected from:

1) halogen,

2) hydroxy, 3) Ci-₃ alkyl,

4) Ci-₃ alkoxy,

5) CF₃, f) C₂-6 alkenyl, g) Ci-6 alkyl CO_nR^a, wherein n selected from 1 and 2, R^a selected from: I) Ci_-6 alkyl,

2) H, h) Phenyl, i) Substituted phenyl with 1 to 3 substituents selected from:

1) halogen,

2) hydroxy,

3) Q.₃ alkyl, 4) Ci.₃ alkoxy,

5) CF₃, j) Benzyl, k) Substituted benzyl with 1 to 3 substituents selected from:

1) halogen, 2) hydroxy,

3) Ci.3 alkyl,

4) C₁J₃ alkoxy,

5) CF₃,

1) C₂-₆ alkyl substituted with phenyl, m) C₂-6 alkyl substituted with phenyl, the phenyl group may be substituted with 1 to 3 substituents selected from:

1) halogen,

2) hydroxy,

3) C₃ alkyl, 4) C_L3 alkoxy,

5) CF₃, n) R^b, o) C,^ alkyl substituted with R^b,

Wherein each R^b is 5 or 6 membered heteroaromatic ring containing 1 to 2 heteroatoms selected from oxygen, nitrogen and sulfur, the ring could be substituted or not on carbon or nitrogen with 1 to 3 substituents selected from:

1) halogen,

2) hydroxy, 3) Ci.₃ alkyl, 4) C i-3 alkoxy,

5) CF₃,

R³ and R⁴ are independently selected from: a) H₅ b) C₆ alkyl, c) Halogen, d) Hydroxy., e) Phenylthio, f) Substituted phenylthio with 1 to 3 substituents selected from: 1) halogen,

2) hydroxy,

3) C,_₃ alkyl,

4) Cu alkoxy,

5) CF₃, g) Benzyl, h) Substituted benzyl with .1-3 substituents selected from:

1) halogen,

2) hydroxy,

3) C₁^ alkyl, 4) Ci-₃ alkoxy,

5) CF₃, R⁵ is selected from: a) CO₂R⁰, wherein R^c is selected from:

1) C_1-6 alkyl, 2) H,

3) sodium or other pharmaceutical acceptable salt, b) P(O)(OR¹¹XOR⁶)- wherein R^d and R^e could be same or not and that are selected from:

1) C_w alkyl, 2) H,

3) sodium or other pharmaceutical acceptable salt. Certain preferred embodiments include compounds which are based on the 2- pyridinone (ρyridin-2-one) scaffold in which the diketo acid moiety is at the 3-position of the pyridinone ring:

wherein R¹ and R² are independently benzyl groups or independently substituted benzyl groups with 1 to 3 substituents on the phenyl rings selected from fluorine, chlorine, C₁^ alkyl, C₂-₄ alkenyl, methoxy;

wherein R³ is H, C₁-_S alkyl, C2-₃ alkenyl, fluorine, chlorine, methoxy; wherein R⁴ is H, F, Cl, OH wherein R⁵ is CO₂H or P(O)(OH)₂ or a pharmaceutically acceptable salt thereof.

Also included within the present invention are pharmaceutical compositions preferably useful for inhibiting HIV integrase, comprising of an effective amount of a compound of this invention, and a pharmaceutically acceptable carrier, additive or excipient. Pharmaceutical compositions useful for treating infection such as by HIV or for treating AIDS or ARC are also included by the present invention. The present invention also includes methods for inhibiting the viral enzyme, HIV integrase, and a method of inhibiting HIV growth or replication, or treating an HIV infection or for treating AIDS or ARC. In addition, the present invention is directed to a pharmaceutical composition comprising, in combination, a therapeutically effective amount of a compound of the present invention in combination with a therapeutically effective amount of an agent for the treatment of AIDS selected from (i) an AIDS or HIV antiviral agent, (ii) an anti-infective agent, (iii) an immunomodulator, (iv) other useful therapeutic agents including antibiotics and other antiviral agents. The compounds of the present invention may have regioϊsomers with respect to the pyridinone scaffold and R¹, R², R³ and R⁴ and these regioisomeric forms are included in the present invention. The compounds may have geometric isomers and these forms are included in the present invention.

Tautomeric forms may also exist with compounds of the present invention. Thus, the terminology "and tautomers thereof is used in describing tautomeric forms of compounds of formula I such as Ia and Ib (shown below). By naming compounds as being represented by the general formula I and tautomers thereof, it is understood that for the purposes of the present invention that tautomers Ia and Ib are also included. Similarly, by referring to compound (Ia), it is understood for the purposes of the present application that tautomers (I) and (Ib) are also intended. The same holds true for references to tautomer (Ib).

When the variables involving R¹, R², R³, R⁴ and R⁵ occur more than once in any formula I, the definition on each occurrence is independent of its definition at every other occurrence. Regioisomeric pyridinones, in addition to those structurally identified, are also part of this invention. Combinations of pyridinones and variables are permissible only if, in context, such combinations result in stable compounds.

The compounds of the present invention are useful in the inhibition of HIV integrase, the prevention or treatment of infection by HIV and in the treatment of the disease known as AIDS. Treating AIDS or preventing or treating infection by HIV is defined as including the treatment of a wide range of states of HIV infection: AIDS, ARC and actual or potential exposure to HIV (e.g., through blood transfusion, exchange of body fluids, bites, needle punctures, exposure to infected patient blood during medical or dental procedures, and other means).

Other applications are also part of this invention. For example, the compounds of this invention are useful in the preparation and execution of screening assays for antiviral compounds including in the isolation of viral enzyme mutants and in further understanding of the enzyme, HIV integrase.

The present invention also provides for the use of a compound of structural formula (I) to make a pharmaceutical composition useful for inhibiting HIV integrase and in the treatment of AIDS or ARC. The compounds of the present invention may be administered in the form of "well- known pharmaceutically acceptable" salts. The latter is intended to include all acceptable salts such as acetate, lactobionate, benzenesulfonate, laurate, benzoate, malate, bicarbonate, maleate, bisulfate, mandelate, bitartrate, mesylate, borate, methylbromide, bromide, methylnitrate, calcium edetate, camsylate, mucate, carbonate, napsylate, chloride, nitrate, clavulanate, N-methylglucamine, citrate, ammonium salt, dihydrochloride, oleate, edetate, oxalate, edisylate, pamoate, estolate, palmitate, esylate, fumarate, phosphate, diphosphate, gluceptate, polygalacturonate, gluconate, salicylate, glutamate, stearate, glycollylarsanilate, sulfate, hexylresorcinate, subacetate, hydrabamine, succinate, hydrobromide, tannate, hydrochloride, tartrate, hydroxynaphthoate, teoclate, iodide, tosylate, isothionate, triethiodide, lactate, panoate, valerate, and others which can be used as a dosage form for modifying the solubility or hydrolysis characteristics or can be used in sustained release or pro-drug formulations. The pharmaceutically acceptable salts of this invention include those with counterions such as sodium, potassium, calcium, lithium, magnesium, zinc, and from bases such as ammonia, ethylenediamine, N-methyl-glutamine, lysine, arginine, ornithine, choline, N, N'-dibenzylethylenediamine, chloroprocaine, diethanolamine, procaine, N- benzylphenethylamine, diethylamine, piperazine, tris(hydroxymethyl)arninomethane, and tetramethylammonium hydroxide. Also, in the case of a carboxylic acid (-COOH) or an alcohol group being present, pharmaceutically acceptable esters can be employed, e.g., acetate, maleate, pivaloyloxymethyl and others, more preferably C1-C2₀ esters and those esters known in the art for improving solubility or hydrolysis characteristics for use as sustained release or pro- drug formulations. Pharmaceutically acceptable esters can also be employed in the case where a phosphonic acid group [-PO(OH)₂] is present. Diketo phosphonic acids attached to pyridinone scaffolds are also part of this invention.

Therapeutically effective amounts of the compounds of the present invention may be administered to patients orally, parenterally, by inhalation spray, or rectally, in dosage unit formulations containing pharmaceutically-acceptable carriers, adjuvants and vehicles including nanoparticle drug delivery approaches. The term "pharmaceutically acceptable" is meant to infer that the carrier, diluent, excipient or other additive must be compatible with the other ingredients of the formulation and not deleterious to the patient or recipient. Pharmaceutical compositions may be in the form of orally-administrable suspensions or tablets, nasal sprays and injectible preparations (injectible aqueous or oleagenous suspensions or suppositories). This method of treatment is part of the invention. The administration approaches used (orally as solution or suspension, immediate release tablets, nasal aerosol or inhalation, injectible solutions or suspensions or rectally administered in the form of suppositories) involve techniques that are well-known in the art of pharmaceutical formulation.

The compounds of this invention can be administered orally to humans in a preferred form (such as tablets) and in a preferred dosage range of about 0.1 to 200 mg/kg body weight in divided doses. The specific dose level and frequency of dosage for any particular patient may be varied and will depend upon a variety of factors including compound activity, compound metabolism and duration of action, patient age, body weight, general health, sex, diet, mode and time of administration, rate of excretion, drug combination, the severity of the particular condition, and the condition of the patient undergoing therapy.

The present invention also includes therapeutically effective combinations of the HIV integrase inhibitor compounds of formula I with one or more other therapeutic agents such as AIDS antivirals, other antiviral agents, immunomodulators, antiinfectives, antibiotics, vaccines or other therapeutic agents as otherwise described herein. Some examples are given below.

ANTIVIRAL AGENTS. ANTI-INFECTIVES, IMMUNOMODULATORY

OPPORTUNISTIC INFECTION DRUGS. OTHER RELEVANT DRUGS IN AIDS

Drug Name Manufacturer Therapeutic Use

097 Hoechst/Bayer HIV infection, AIDS,

ARC (NNRT inhibitor)

Amprenivir Glaxo Wellcome HIV infection, AIDS,

141W94, GW141 ARC (protease inhibitor)

Abacavir (1592U89) Glaxo Wellcome HIV infection, AIDS,

GW 1592 ARC (RT inhibitor)

Acemannan Carrington Labs (Irving, ARC

TX)

Acyclovir Burroughs Wellcome HIV infection, AIDS,

ARC, in combination with AZT

AD-439 Tanox Biosystems HIV infection, AIDS,

ARC

AD-519 Tanox Biosystems HIV infection, AIDS,

ARC

Adefovir dipivoxil Gilead Sciences HTV infection

AL-721 Ethigen (Los Angeles, ARC, PGL HIV positive,

CA) AIDS

Alpha Interferon Glaxo Wellcome Kaposi's sarcoma, HIV in combination w/Retrovir

Ansamycin Adria Laboratories ARC

LM 427 (Dublin, OH)

Erbamont (Stamford, CT)

Antibody which Advanced Biotherapy AIDS, ARC neutralizes pH labile Concepts (Rockville, alpha aberrant MD)

Interferon

AR 177 Aronex Pharm HTV infection, AIDS,

ARC

Beta-fluoro-ddA National Cancer Institute ATDS-associated diseases BMS-232623 Bristol-Myers HIV infection, AIDS. (CGP-73547) Squibb/Novartis ARC (protease inhibitor)

BMS-234475 Bristol-Myers HIV infection, AIDS, (CGP-61755) Squibb/Novartis ARC (protease inhibitor)

CI-1012 Warner-Lambert ffiV-1 infection

Cidofovir Gilead Science CMV retinitis, herpes, papillomavirus

Curdlan sulfate AJI Pharma USA HIV infection

Cytomegalovirus Medlmmune CMV retinitis Immune globin

Cytovene Syntex Sight threatening CMV Ganciclovir Peripheral CMV Retinitis ddl Bristol-Myers Squibb HIV infection, AIDS, Dideoxyinosine ARC; combination with AZT/d4T

DMP-450 AVID (Camden, NJ) HIV infection, AIDS, ARC (protease inhibitor)

Efavirenz (DMP-266) DuPont Merck HIV infection, AIDS, ARC (non-nucleoside RT inhibitor

ELlO Elan Corp, PLC HIV infection (Gainesville, GA) Famciclovir Smith Kline Herpes zoster, herpes simplex

FTC Emory University HIV infection, AIDS,

ARC (reverse transcriptase inhibitor)

GS 840 Gilead HIV infection, AIDS, ARC (reverse transcriptase inhibitor)

HBY097 Hoechst Marion Roussel HIV infection, AIDS, ARC (non-nucleoside reverse transcriptase inhibitor)

Hypericin VIMRx Pharm. HIV infection, AIDS, ARC

Recombinant Human Triton Biosciences AIDS, Kaposi's sarcoma, Interferon Beta (Almeda, CA) ARC

Interferon alfa-n3 Interferon Scienes ARC, AIDS Indinavir Merck HIV infection, AIDS, ARC, asymptomatic HIV positive; combination with AZT/ddl/ddC

ISIS-2922 ISIS Pharmaceuticals CMV retinitis KNI-272 Natl. Cancer Institute HTV-associated diseases Lamivudine, 3TC Glaxo Wellcome HIV infection, AIDS, ARC (reverse transcriptase inhibitor); also with AZT

Lobucavir Bristol-Myers Squibb CMV infection Nelfinavir Agouron Pharmaceuticals HIV infection, AIDS, ARC (protease inhibitor)

Nevirapine Boeheringer Ingleheim HIV infection, AIDS, ARC (RT inhibitor) Novapren Novaferon Labs, Inc. HIV inhibitor (Akron, OH)

Peptide T Peninsula Labs (Belmont, AIDS Octapeptide Sequence CA)

Trisodium Astra Pharm. Products, CVV retinitis, HIV Phosphonoformate Inc. infection, other CMV

PNU- 140690 Pharmacia Upjohn HIV infection, AIDS, ARC (protease inhibitor)

Probucol Vyrex HIV infection, AIDS RBC-CD4 Sheffield Med. Tech HIV infection, AIDS, (Houston, TX) ARC

Ritonavir Abbott HIV infection, AIDS, ARC (protease inhibitor)

Saquinavir Hoffinann-LaRoche HIV infection, AIDS, ARC (protease inhibitor)

Stavudine; d4T Bristol-Myers Squibb HIV infection, AIDS,

Didehydrodeoxythymidine ARC

Valaciclovir Glaxo Wellcome GenitaLHSV & CMV infections

Virazole Ribavirin Viratek/ICN (Costa Asymptomatic HIV Mesa, CA) positive, LAS, ARC

VX-478 Vertex HIV infection, AIDS, ARC

Zalcitabine Hoffinann-LaRoche HIV infection, AIDS, ARC with AZT

Zidovudine; AZT Glaxo Wellcome HIV infection, AIDS, ARC, Kaposi's sarcoma, in combination with other therapies

Tenofovir diisoproxil Gilead HIV infection, AIDS, fumarate salt (Viread^®) (RT inhibitor)

Combivir^® GSK HIV infection, AIDS, (RT inhibitor)

Abacavir succinate (or GSK HIV infection, AIDS, Ziagen^®) (reverse transcriptase inhibitor)

Fuzeon^® (or T-20) Roche/Trimeris HIV infection, AIDS₅ viral Fusion inhibitor

AS-101 Wyeth-Ayerst AIDS

Bropirimine Pharmacia Upjohn Advanced AIDS

Acemannan Caπington Labs, Inc. AIDS, ARC (Irving, TX)

CL246, 738 American Cyanamid AIDS, Kaposi's sarcoma Lederle Labs

ELlO Elan Corp, PLC HIV infection (Gainesville, GA)

FP-21399 Fuki Immuno PHARM Blocks HIV fusion with CD4+ cells

Gamma Interferon Genentech ARC, in combination w/TNF

Granulocyte Genetics Institute AIDS Macrophage Colony Sandoz Stimulating Factor

Granulocyte Hoeschst-Roussel AIDS Macrophage Colony Immunex Stimulating Factor

Granulocyte Schering-Plough AIDS, combination Macrophage Colony w/AZT Stimulating Factor HIV Core Particle Rorer Seropositive HIV Immunostimulant

IL-2 Cetus AIDS, in combination Interleukin-2 w/AZT

IL-2 Hoffinan-LaRoche AIDS, ARC, HIV, in Interleukin-2 Immunex combination w/AZT

IL-2 Chiron AIDS, increase in CD4 Interleukin-2 cell counts (aldeslukin)

Immune Globulin Cutter Biological Pediatric AIDS, in Intravenous (Berkeley, CA) combination w/AZT (human)

IMREG-I Imreg (New Orleans, LA) AIDS, Kaposi's sarcoπ ARC, PGL IMREG-2 Imreg (New Orleans, LA AIDS, Kaposi's sarcon ARC, PGL

Imuthiol Diethyl Merieux Institute AIDS, ARC Dithio Carbamate

Alpha-2 Interferon Schering Plough Kaposi's sarcoma w/AZT, AIDS

Methionine-Enkephalin TNI Pharmaceutical AIDS, ARC (Chicago, IL)

MTP-PE Cϊba-Geigy Corp. Kaposi's sarcoma Muramyl-Tripeptide Granulocyte Amgen AIDS, in combination

Colony Stimulating Factor w/AZT

Remune Immune Response Corp. Immunotherapeutic

rCD4 Genentech AIDS₉ ARC

Recombinant Soluble Human CD4-IgG rCD4-IgG Hybrids AIDS, ARC

Recombinant Soluble Biogen AIDS, ARC Human CD4 Interferon Alfa 2a Hoffinan-LaRoche Kaposi's sarcoma, AIDS, AR, combination w/AZT

SK&F1-6528 Smith Kline HIV infection Soluble T4

Thymopentin Immunobiology Research HIV infection Institute (Annandale, NJ)

Tumor Necrosis Factor Genentech ARC₃ in combination (TNF) w/gamma Interferon

AK602 Kumamoto University HIV infection (entry and Japan fusion inhibitor)

Alovudine Medivir, UK Ltd. HIV infection (nucleoside RT inhibitor)

Amdoxovir RFS Pharma, LLC Treatment of HIV and HBV infections (nucleoside RT Inhibitor)

AMD070 AnorMED, Inc. HIV infection (entry and fusion inhibitor)

Atazanavir (Reyataz) Bristol -Myers Squibb HIV infection (protease inhibitor) AVX754 (apricitabine) Avexa Ltd. HIV infection (nucleoside RT inhibitor Bevirimat Panacos Pharmaceuticals HIV infection (maturation inhibitor) BI-201 Biolnvent HIV infection (gene therapy, blocks HIV tat gene). BMS-378806 Bristol - Myers Squibb HIV infection (entry inhibitor)

BMS-488043 Bristol - Myers Squibb HIV infection (entry and fusion inhibitor)

BMS-707035 Bristol - Myers Squibb HIV infection (integase inhibitor)

C31G Cellegy Pharmaceuticals, HIV infection and other Inc sexually transmitted diseases (STDs)

Carbopol 974P ReProtect, LLC Sexual transmission of HTV

Calanolide A Sarawak MediChem HIV infection (non- Pharmaceuticals, Inc. nucleoside RT inhibitor)

Carrageenan FMC Biopolymer HIV microbicide

Cellulose sulfate Polydex Pharmaceuticals, Prevention of HIV infection Ltd. and other sexually transmitted diseases

Cyanovirin-N Cellegy Pharmaceuticals, Prevention of sexual Inc. transmission of HIV infection

Darunavir Tibotec HIV infection (coadministered with ritonavir)

Delavirdine Pfizer HIV infection (non- nucleoside RT inhibitor)

Dextran sulfate Ueno Fine Chemicals Prevention of transmission Industry, Ltd. of HIV

Didanosine (Videx, Bristol - Myers Squibb HIV infection (nucleoside Videx EC) RT inhibitor)

Efavirenz Bristol - Myers Squibb HIV infection (non- nucleoside RT inhibitor)

Elvucitabine Achillion Pharmaceuticals HIV infection (nucleoside RT inhibitor)

Emtricitabine Gilead Sciences HIV infection (nucleoside

RT inhibitor)

Fosamprenavir (Lexiva) GlaxoSmithKline HIV infection. (protease inhibitor)

Fozivudine tidoxil Heidelberg Pharma HIV infection (entry and fusion inhibitor)

GS 9137 Gilead Sciences HIV infection (integase inhibitor)

GSK-873,140 (aplaviroc) GlaxoSmithKline HIV infection (entry and fusion inhibitor)

GSK- 364735 GlaxoSmithKline HIV infection (integase inhibitor)

GW640385 (brecanavir) GlaxoSmithKline HIV infection (protease inhibitor)

HG0004 Human Genome Sciences HIV infection (entry and fusion inhibitor)

HGTV43 Enzo Therapeutics HIV infection (antisense drug)

Hydroxyethyl cellulose Union Carbide Prevent sexual transmission of HIV

INCB9471 Incyte Corporation HIV infection (entry and fusion inhibitor)

KP-1461 Koronis Pharmaceuticals HIV infection (nucleoside RT inhibitor)

Lopinavir Abbott Laboratories HIV infection (protease inhibitor)

Mifepristone (VGX410, Viral Genomix HIV infection (gene RU486) therapy _^interferes with vpr)

MK-0518 Merck HIV infection (integase inhibitor)

PA-457 (bevirimat) Panacos Pharmaceuticals, Treatment of HI V Inc. (maturation inhibitor)

PoIy(I)-PoIy(Cl 2U) Hemispherx Biopharma, Biological response (Ampligen) Inc. modifier

PPL-100 Merck HIV infection (protease inhibitor) PRO 140 Progenies Pharmaceuticals, HIV infection (entry and Inc. fusion inhibitor)

PRO 542 Progenies Pharmaceuticals, HIV infection (entry and Inc. fusion inhibitor)

PRO 2000 Indevus Pharmaceuticals, Microbicide Inc.

Racivir Pharmasset, Inc. HIV infection (nucleoside RT inhibitor)

SCH-D (vicriviroc) Schering - Plough Corp HIV infection (entry and fusion inhibitor)

SPOlA Samaritan Pharmaceuticals HIV infection (entry and fusion inhibitor)

SPL7013 Starpharma Microbicide

TAK-652 Takeda HIV infection (entry and fusion inhibitor)

Tipranavir (Aptivus) Boehringer Ingelheim HIV infection (protease Pharmaceuticals inhibitor)

TNX-355 Tanox, Inc. HIV infection (entry and fusion inhibitor)

TMC 125 (etravirine) Tibotec HIV infection (non- nucleoside RT inhibitor)

UC-781 Cellegy Pharmaceuticals, Microbicide Inc

UK-427.857 (Maraviroc) Pfizer HIV infection (entry and fusion inhibitor)

Valproic acid Abbott Treating seizures in HIV infection

VRX496 VIRxSYS Gene therapy

Zalcitabine (Hivid) Roche HIV infection (nucleoside RT inhibitor)

Valganciclovir (Valcyte) Roche Antiviral (CMV retinitis in AIDS)

Clindamycin with Primaquine Pharmacia Upjohn PCP Fluconazole Pfizer Cryptococcal meningitis, candidiasis

Pastille Squibb Corp. prevention of oral Nystatin Pastille candidiasis

Ornidyl Merrell Dow PCP Eflornithine

Pentamidine LyphoMed (Rosemont, PCP treatment Isethionate (IM & IV) IL)

Trimethoprim Antibacterial

Trimethoprim/sulfa Antibacterial

Piritrexim Burroughs Wellcome PCP treatment

Pentamidine isethionate Fisons Corporation PCP prophylaxis Spiramycin Rhone-Poulenc Cryptosporidia! diarrhea

Intraconazole-R51211 Janssen Pharm Histoplasmosis; cryptococcal meningitis

Trimetrexate Warner-Lambert PCP Daunorubicin NeXstar, Sequus Karposi's sarcoma

Recombinant Human Ortho Pharm. Corp. Severe anemia assocated Erythropoietin w/AZT therapy

Recombinant Human Serono AIDS-related wasting, Growth Hormone cachexia

Megestrol Acetate Bristol-Myers Squibb Treatment of anorexia associated w/AIDS

Testosterone Alza, Smith Kline AIDS-related wasting

Total Enteral Nutrition Norwich Eaton Diarrhea and Pharmaceuticals malabsorption in AIDS

Aldesleukin (Proleukin) Chiron Corp Biological response modifier

Amphotericin B (Abelecet, Pfizer, Bristol - Myers Antifungal AmBisome, Amphocin, Squibb Amphotec, Fungizone) Azithromycin (Zithromax) Pfizer Antibacterial antibiotic

Calcium hydroxyapatite Bioform Medical, Inc. Dermal filler (Radiesse

Doxorubicin (liposomal) Ortho Biotech, Alza Antineoplastic (Doxil) Coφoration

Dronabinol (Marinol) Unimed Pharmaceuticals, Inc. Antiemetics

Entecavir (Baraclude) Bristol-Myers Squibb Antiviral

Epoetin alfa (Epogen, Ortho Biotech Anemia Procrit)

Etoposide (Etopophos Pfizer, Bristol-Myers Antineoplastic (phosphate salt), Toposar, Squibb VePesid)

Fluconazole (Diflucan) Pfizer Antifungal

Interferon alfa-2 (Intron A Roche, Schering -Plough Biological response (2b), Roferon-A (2a) modifiers

Isoniazid (Nydrazid) Sandoz, Hoffmann La- Antimycobacterial Roche

Itraconazole (Sporanox) Ortho Biotech, Janssen Antifungal Pharmaceutica

Megestrol (Megace, Bristol - Myers Squibb Anticachectic Megace ES)

Paclitaxel (Onxol, Taxol) Bristol - Myers Squibb, Antineoplastic rVAX Pharmaceuticals

Peginterferon alfa-2 (PEG- Roche, Schering -Plough Antiviral Intron (2b), Pegasys (2a))

Pentamidine (Nebupent) American Pharmaceutical Antiprotozoal Partners, Fujisawa Health Care, Inc.

Poly-L-lactic acid Dermik Laboratories Dermal Filler (Sculptra)

Rifabutin (Mycobutin) Pharmacia Corporation Antimycobacterial

Rifampin (Rifadin, Aventis Pharmaceuticals Antimycobacterial Rimactane) Somatropin Pharmacia Corporation, Synthetic human growth Serono Inc hormone

Sulfamethoxazole / Alpha care Inc, Women Antibacterial Trimethoprim (Bactrim, First Health Care, King Septra) (Serostim) Pharmaceuticals

Testosterone (Androderm, Pfizer Inc, Unimed Androgens Androgel, Depo- Pharmaceuticals, Inc., Alza Testosterone) Corporation, Watson Laboratories

Trimetrexate (Neutrexin) United States Bioscience Antiprotozoal Inc, Medimmune, Inc.

The combinations of the compounds of this invention with AIDS antivirals (including anti-HIV integrase-based antivirals), other antivirals, immunomodulators, anti- infectives, antibiotics, vaccines, other therapeutic agents are not limited to the list in the above Table, but includes, in principle, any combination with any pharmaceutical composition useful for the treatment against infection by HIV or for treating AIDS or ARC. Preferred combinations are simultaneous or alternating treatments of a compound of the present invention and a protease inhibitor (e.g., indinavir, nelfinavir, ritonavir, saquinavir and others), a reverse transcriptase inhibitor [nucleoside (e.g., AZT, 3TC, ddC, ddl, d4T, abacavir and others, and/or non-nucleoside (e.g., efavirenz, nevirapine, and others), or some combination of two or more of these inhibitors (see Table above). A few representative examples of relevant patents citing combinations are: EPO 0,484,071, U.S. 5, 413,999, WO 9962513.

In such combinations the compound of the present invention and other active agents may be separately administered or concurrently administered. In addition, the administration of one element may be prior to, concurrent to, or subsequent to the administration of other agent(s).

The combinations of the compounds of this invention with AIDS antivirals (as described above and as otherwise set forth and described hereinbelow, other antivirals, immunomodulators, anti-infectives, antibiotics, vaccines, other therapeutic agents are not limited to the list in the above Table, but includes, in principle, any combination with any pharmaceutical composition useful for the treatment against infection by HIV or for treating AIDS or ARC. Preferred combinations are simultaneous or alternating treatments of a compound of the present invention and a protease inhibitor (e.g., indinavir, nelfinavir, ritonavir, saquinavir among others), a reverse transcriptase inhibitor [nucleoside (e.g., AZT, 3TC, ddC, ddl, d4T, abacavir and others, and/or non-nucleoside (e.g., efavirenz, nevirapine, and others), or some combination of two or more of these inhibitors (see Table above). A few representative examples of relevant patents citing combinations are: EPO 0,484,071, U.S. 5, 413,999, WO 9962513.

In such combinations the compound of the present invention and other active agents, for example as described hereinbelow, may be separately administered or concurrently administered in effective amount. In addition, the administration of one element may be prior to, concurrent to, or subsequent to the administration of other agent(s).

The following examples of drugs or bioactive agents effective against HIV or having benefits when used in the treatment of HIV or secondary indications/conditions of HIV, including AIDS/ ARC and secondary conditions or disease states such as Kaposi's sarcoma, hepatitis B virus infections, etc., which may be combined with compounds according to the present invention in providing pharmaceutical compositions and methods of treating HIV infections or their secondary conditions or disease states. When included in pharmaceutical compositions or methods of treatment, these drugs or bioactive agents are included in effective amounts to resolve the condition or disease state for which the compounds have been administered.

• (-)βDioxolane-G; DXG;

• (-)β-Arctigenin; Arctigenin ; • (-)-Carbovir; (-)-C-D4G; (-)-Carbovir;

• (-)-β-D-2,6-Diaminopurine dioxolane;Amdoxovir; DAPD; APD

• (+)-2'-Deoxy-3'-oxa-4^l-thiocytidine; dOTC (+)

• (+)-2^I-Deoxy-3^t-oxa-4'-thio-5-fluorocytidine; dOTFC (+) • (+/-)-Cyclobut-G; A-69992; (+/-)-Lobucavir; C-Oxt-G; Cyclobut-G ; C-Oxetanocin-G

• (R)-2QuinCOAsnPhe[CHOHCH2]PipCONHtBu

• (R)-3.6-Diamino-N-(aminomethyl)hexanamide; Bellenamine • (R)-PMPA; (R)-9-(2-Phosphonylmethoxypropyl)adenine; PMPA-(R); Tenofovir

• (R)-PMPDAP; PMPDAP-(R)

• (S)-PMPA; (S)-9-(2-Phosphonylmethoxypropyl)adenine; PMPA(S)

• (S)-9-(2-Phosphonylmethoxypropyl)adenine; (S)-PMPA

• α-APA; R89439; Loviride

• α-APA deriv.; R87232

• α-APA deriv.; R88703

• α-APA enantiomer; R90385

• α-L-AZT; AZT-α-L • α-L-DXC; α-L-Dioxalane-C; DXC-α-L-

• α-L-FTC; FTC-α-L-

• α-Monofluoromethyldehydroornitbine methyl ester; MFMOME

• 1,1 '-Azobisformamide; ADA; Azodicarbonamide • l^l l-Octylamino-lO-hydroxyundecyO-SJ-dimethylxanthineϊ CT^Syό

• l-(2',3'-Dideoxy-2^l-fluoro-β-D-threo-pentofuranosyl)cytosine; Ro 31-6840

• l-(2'-Fluoro-2\3'-dideoxy-B-D-ery1±ιro-pentofuranosyl)1±ιymine; 2'FddT

• l-(2OHPr)-4-Substit-piperazine, thienyl carbamate deriv.

• l-(2OHPr)-4-Substit-piperazine, thienyl carbamate deriv. • l-(2OHPr)-4-Substit-piperazine, thienyl carbamate deriv.

• l-(2OHPr)-4-Substit-piperazine, thienyl carbamate deriv.

• l-[(2-Hydroxyethoxy)methyl]-6-(3-methylphenyl)thio)thymine; HEPT-M ^•

• l-[(2-Hydroxyethoxy)methyl]-6-(phenylthio)-2-thiothymine; HEPT-S

• l-[(2-Hydroxyethoxy)methyl]-6-(phenylthio)thymine; HEPT • 1-Deoxynojirimycin ; Deoxynojirimycin

• 141 W94; VX-478; Amprenavir; Agenerase®; Approved

• 1592U89 Succinate; Abacavir Succinate; Ziagen® Approved

• 1-Arninooxyethylamine; AEA • l-Methoxyoxalyl-3,5-dicaffeoylquinic acid; 1-MO-3.5-DCQA; Dicaffeoylquinic acid deriv.

• lOH-2(Cbz-Tle)3PhPr [14]paracyclophane deriv.

• 10H-2(Cbz-ValNH)3PhPr [13]metacyclophane deriv.

• 10H-2(Cbz-ValNH)3PhPr [13]paracyclophane deriv. • 10H-2(Cbz-ValNH)3PhPr [14]paracyclophane deriv.

• 10H-2(Cbz-ValNH)3PhPr [17]paracyclophane deriv.

• 12-Deoxyphorbol-13-(3E,5E-decadienoate); Phorbol deriv.

• I6.alpha.-Bromoepiandrosterone; Epi-Br; ; Inactivin; HE 2000; HE2000; PPB2; DHEA deriv. • l-β-D-arabinofuranosyl-5-(2-bromovinyl)uracil; BV-ara-U; BVaraU; BV ara-U;

Sorivudine; SQ-32756; Bravavir; Brovavir; Usevir; YN-72; Bromovinyl araU; BVAU

• 2^l,3¹-Didehydro-3'-deoxycytidiBe; D4C

• 2^I,3'-Dideoxydidehydroguanosine; D4G • 2',3'-Didehydro-3'-deoxythymidine; D4T; Stavudine; Zerit® Approved

• 2^l,3^I-Dideoxy-3'-fluoro-4-ttaothymidine; 3'-F-4-Tbio-ddT

• 2^l,3'-Dideoxy-3'-fluoro-5-bromouridine; FddBrU

• 2',3'-Dideoxy-3^l-fluoro-5-chlorocytidine; 3'-F-5-Cl-ddC

• 2',3'-Dideoxy-3'-fluoro-5-chlorouridine; 935U83; 5-Chloro-2',3'-dideoxy-3'-fluorouridine; FddClU; Raluridine

• 2',3'-Dideoxy-5-ethylcytidine; 5-Et-ddC

• 2',3'-Dideoxyadenosine; D2A; ddAdo; ddA

• 2'₅3'-Dideoxydidehydroadenosine; d4A

• 2',3'-Dϊdeoxyguanosine; D2G; ddG • 2',3^l-Dideoxy-3^I-hydroxymethyl cytidine; 3'-Hydroxymethyl-ddC; BEA-005

• 2,5'-Anhydro-3'-azido-2^l,3'-dideoxyuridine; AZU-2,5'-anhydro

• 2,5'-Anhydro-3'-azido-3^l-deoxythymidine; AZT-2,5'-anhydro

• 2',5UiSiIySpH-OT; TSAO-T

. 2',5'diSilySpiroT; TSAO-me^Λ3T • 2.6-Diamino-2',3'-dideoxypurine-9-ribofuranoside; ddDAPR; DAPDDR; 2,6-Diamino-ddP

• 2,6-Diaminopurine- 2',3'-dideoxydidehydroriboside; ddeDAPR

• 2,6-Diaminopurine-3'-fluoro-2',3^f-dideoxyriboside; 3 -F-ddDAPR

• 2-Aminobenzylstatine Valyl Cbz deriv.; Statine deriv. • 2-Glycine amide-5-chlorophenyl 2-pyrryl ketone; GCPK

• [2-PyridCH2NCH3CO-Val-NHCH(Bz)]CHOHCHOH; A-77003

• 2'-Azido-2'_s3'-dideoxyadenosine; 9-(2'-Azido-2',3'-dideoxy~β-D- erythropentofuranosyl)adenine; 2'-N3ddA • 2'-FddA(B-D-threo); F-ddA; 2'-F-dd-ara-A; 9-(2'-Fluoro-2^I,3'-dideoxy-B-D- threopentafuranosyl)adenine; Lodensine

• 2'-N3ddA (B-D-threo); 9-(2^l-Azido-2',3'-didedxy-β-threopentafVιranosyl)adenine

• 2-NaphCOAsnPhe[CHOHCH2]Pro-OtBu

• 2-Nitrophenylphenylsulfone; NPPS

• 3-(3-Oxo-l-propenyl)-3^I-azido-3'-deoxythymidiiie; 3-(3-Oxo-l-propenyl)AZT

• 3-(Phenylsulfonyl)-indole deriv. ; L-737,126

• 3,5-DCQA; 3,5-Dicaffeoylquinic acid; Dicaffeoylquinic acid

• 3'-Azido-2',3'-dideoxy-5-[(cyanomethyl)oxy]uridine; 3'-N3-5-Cyanomethyloxy-ddU • S'-Azido-^.S'-dideoxy-S-aminouridine; 3'-N3-5-NH2-ddU

• S'-Azido-Z^'-dideoxy-S-aza-ό-deazauridine; C-analog of 3'-N3-ddU

• S'-Azido^'^'-dideoxy-S-bromouridine; 3'-N3-5-Br-ddU; AZddBrU

• S'-Azido^'^'-dideoxy-S-chlorocytidine; 3'-Az-5-Cl-ddC

• 3VAzido-2^3'-dideoxy-5-dime1hylaminouridine; 3'-N3-5-NMe2-ddU • S'-Azido-^S'-dideoxy-S-ethyluridine; 3'-N3-5-EtddU; CS-85; AZddEtU

• 3'-Azido-2',3'-dideoxy-5-fluorocytidine; 3'-N3-5-F-ddC

• 3'-Azido-2^3'-dideoxy-5-:αuorouxidine; AZddFU

. S'-Azido-^^'-dideoxy-S-hydroxyuridine; 3'-N3-5-OH-ddU

• S'-Azido^'.S'-dideoxy-S-iodouridine; 3'-N3-5-I-ddU; AZddIU • 3^l-Azido-2',3'-dideoxy-5-methyaminouridine; 3'-N3-5-NHMe-ddU

• 3'-Azido-2',3'-dideoxy-5-methylcytidine; CS-92; 3'-N3-5-Me-ddC

• S'-Azido^'.S'-dideoxy-S-thiocyanatouridine; 3'-N3-5-SCN-ddU

• S'-Azido-^S'-dideoxy-S-trifluoromethyluridine; 3'-N3-5-CF3-ddU

• 3'-Azido-2',3'-dideoxycytidine; CS-91; 3'-N3-ddC • 3'-Azido-2'_s3^f-dideoxyguanosine; AZG; 3'-N3ddG

• 3¹-Azido-2',3'-dideoxy-N4--5-dimethylcytidine; 3^l-N3-N4-5-diMe-ddC

• 3^I-Azido-2¹,3'-dideoxy-N4-OH-5-methylcytidine; 3'-N3-N4-OH-5-Me-ddC

•

CS-87; 3'-N3ddU; AZdU; Uravidine • 3'-Azido-3'-deoxy-6-azathymidine; 3'AZ-6AzaT

• S-Azido-S'-deoxythymidilyl-CS'^O^'.S'-dideoxy-S'-adenylic acid; AZT-P-ddA

• 3'-Azido-3'-deoxythymidilyl-(5',5^l)-2^l,3^l-dideoxy-5^l-adenylic acid, 2-cyanoethyl ester; AZT- P(CyE)-ddA • 3'-Azido-3¹-deoxythymidilyl-(5^I,5¹)-2^l,3'-dideoxy-5'-inosinic acid; AZT-P-ddl

• S'-Azido-S'-deoxythymidine-S'-CbutylmethoxyvalinyOphosphatej S'MeOValPOSCB^AZT

• S'-Azido-S-chloro-^S'-dideoxyuridine; AzddClUrd; AzddClU

• 3'-Deoxythymidine; ddT

• 3'-FddA (B-D-Erythro); Q-CS'-Fluoro^'^'-dideoxy-B-D-erythxopentafuranosy^adenine • 3'-FddC; S'-Fluoro^'^'-dideoxycytidine

• 3'-FddG; 3'-Fluoro-2',3'-dideoxyguanosine

• 3'-FddT; Alovudine; FddT; FddThD; 3'-FLT; FLT - 3'-FddU; 3'-Fluoro-2',3'-dideoxyuridine

• 3'-Fluoro-2',3'-dideoxy-5-iodouridine; FddIU • 3'-N3-ddA; 9-(3'-Azido-2^3^l-dideoxy-B-D-erythropentafuranosyl)adenine

• 3TC; Lamivudine; Epivir® Approved;

• Lamivudine & Zidovudine; Combivir® 3TC & AZT; Approved

• 4'-Acetoamidophenyl4-guadinobenzoate; AGB • 4'-Az-3'-dT; 4'-Azido-3'-deoxythyinidine

• 4'-Az-5CldU ; 4'-Azido-5-chloro-2'-deoxyuridine

• 4'-AzdA; 4'-Azido-2'-deoxyadenosine

• 4'-AzdC; 4'-Azido-2'-deoxycytidine

• 4'-AzdG; 4'-Azido-2'-deoxyguanosine • 4'-AzdI; 4'-Azido-2'-deoxyinόsine

• 4'-AzdU; 4'-Azido-2'-deoxyuridine

• 4'-Azido-2'-deoxy-β-D-erythro-pentofuranosyl-5-raethyl-2,4-dioxopyrimidine; 4'- Azidothymidine

• 4'-Cyanothymidine; 4'-CN-T • 4-Methyl-5-(pyrazinyl)-3H-l,2-dithiole-3-thione; Oltipraz

• 5'-[(1 ,4-Dihydro-l-methyl-3-pyridinylcarbonyl)oxy]-3'-azido-2',3^l-deoxythymidine; DP- AZT; HP-AZT; AZT Prodrug; AZT-DHP • 5'-[[(Z)-4-amino-2-butenyl]methylamino]-5'-deoxyadenosine; MDL 73811

• S'-Alkylglycosidecarbonate of 3'-azido-3'-deoxythymidine; AcNHGlc-hexyl-CCβ AZT . 5C13PhS-2IndolCONH2

• 5-Fluoro-2',3'-dideoxycytidine; 5-F-ddC • 5-Methyl-3'-azido-2',3'-dideoxyisocytidine; MeAZddlsoC

• 6-O-Butanoylcastanospermine; BuCast; MDL 28,574; Celgosivir

• 6-Chloro-9-(2,3-dideoxy-b-D-glyceropentofuranosyl)-9H-purine; D2C1P; 6-Chloro-ddP; CPDDR; 6Cl-ddP • 6-Dimethylaminopurine-2'_>3'-dideoxyriboside; N-6-dimethylddA; DMAPDDR

• 7-Chloro-N-methyl-5-(lH-pyrrol-2-yl)-3H-l,4-benzodiazepin-2-amine ; Ro 24-7429

• 7-Chloro-5-(2-pyrryl)-3H-l,4-benzodiazepin-2(H)-one ; Ro 5-3335

• 8-Chloro-TIBO; Tivirapine; R86183

• 9-(2,3-Dideoxy-β-D-ribofiαranosyl)-6-(methylthio)purine; D2SMeP

• 9-[Bis(OHMe)cBu]A; A-69463; Cyclobutyl-A; Cyclobut-A ; C-oxetanocin A

• A-76890 . A-77212

• A-80987; Ritonavir deriv.

• A-81525; Ritonavir deriv.

• A-83962; Ritonavir deriv. • A-98881 ; Azacyclic urea deriv.

• AA; L-ascorbic acid; Calcium Ascorbate

• AAP-BHAP; U-104489; PNU-104489

• Abacavir Sc Lamivudine & Zidovudine; Trizivir® ABC & (-)-3TC & AZT

• ABT-378; Lopinavir; Component of Kaletra; Aluviran® • ABT-378 & ABT-538; Kaletra^®; Lopinavir & Ritonavir; Aluviran^® & Norvir^®

• ABT-538; Norvir®; Ritonavir; Component of Kaletra; Approved

• Acemannan

• Adefovir; PMEA; GS-0393 • Adefovir dipivoxil; BisPom PMEA; GS-840; Preveon®

• AG- 1343; Viracept®; Nelfinavir; Approved

• AG1350; LY316957; Nelfinavir-octahydro-thienopyridine analog

• AHPBA analog; R-87366 • Alpha-lipoic acid; α-Lipoic acid; Thioctic acid

• ALX40-4C

• AMD3100; JM3100

• Amprenavir phosphate; VX-175; GW433908; GW433908A (*Sodium Salt*); GW433908G (*Calcium Salt*); Fosamprenavir • Ancer 20; Z-100

• Anti-sense 25-mer phosphorothioate; GEM91

• Atazanavir; CGP-73547; BMS-232632; BMS 232632; Zrivada; Latazanavir; Reyataz®

• Atevirdine; U-87201E; BHAP deriv.

• Aurintricarboxylic acid; Dupont ATA; Dupont DA639; SD-095345; ATA • AY 9944; trans- l,4-Bis(2-dichlorobenzylaminoethyl)cyclohexane dichlorhydrate

• AZT; Zidovudine; Azidothymidine; Retrovir®

• AZT-PO3(CH3)-AZT; O₅O^l-Bis(3'-azido-3^l-deoxythymidin-5'-yl)methylρhosphonate

• Baicaliπ; TJN-151 • Betulinic acid; Mairin

• Betulinic acid, 3-O-(3',3'-dimethylsuccinate)

• BHAP deriv.

• BHAP deriv. • BHAP deriv.

• BHAP deriv.

• BHAP deriv.; Rescriptor® ; Delavirdine; U-90152

• BHAP deriv.; U-88204E

• BI-RG-587; Nevirapine; Viramune® Approved • BILA 1906 BS

• BILA 2011 BS; Palinavir

• BILA 2185 BS

• Bis(2-nitrophenyl)sulfone; Bis(2NO2Ph)SO2; NSC633001 • bis-ValHOEt-N2aza-peptide isostere; CGP 53820

• bis-ValHOEt-N2aza-ρeptide isostere; CGP 53820 analog

• BMS- 186318

^• • BocPhe[CHOH(CH2)3CH=CHPhCO]IleAMBI; L-687,908 . BzOCValPhe[diCHOH(RR)]PheValBzOC

• BzOCValPhe[diCHOH(SS)]PheValBzOC

• C2-Sym Phosphinic amide deriv. (HOECHST AG)

• Calanolide A ; NSC675451 • Calanolide B

• Capravirine; S-1153

• Castanospermine

• CbzAF(CHOHCH2)AVVOMe

• Cbz-Asn-Apns-Pro-NH-tBu; KNI-102 • CGP 61755; Lasinavir

• CGP 64222

• CNI-H0294

• Coactinon;I-EBU; HEPT deriv.; MKC-442; Emivirine

• Conocurvone; NSC650891 • Coviracil; (-)FTC; (-^^'-Dideoxy-S-fluoro-S'-thiacytidine; Emtricitabine; Emtriva

• C-Oxetanocin-G; A-69992; (-t--)Lobucavir; C-Oxt-G; Cyclobut-G; (÷-)Cyclobut-G

• Crixivan®; Indinavir; MK639; L-735,524; Approved

• Curdlan Sulfate

• CV-N; Cyanovirin-N • Cyclic Urea Amide; SD146

• Cyclosporin A; Sandimmune®

• [Me-Ile-4] Cyclosporin A; SDZ NIM 811

• D4A (L); L-2¹,3'-Didehydro-2^l,3'-dideoxyadenosine • D4FC; D-D4FC; ^S'-Didehydro^'.S'-dideoxy-S-fluorocytidine; DPC 817

• D4FC (L); L^'^'-Didehydro^'^'-dideoxy-S-fluorocytidine

• D4G (L); L^'^'-Didehydro^S'-dideoxyguanosine

• D4I (L); L-2',3'-Didehydro-2^l.,3^I-dideoxyinosine

• DABO • ddC; Dideoxycytidine; Zalcitabine; Hivid®

• ddl; Dideoxyinosine; Didanosine; Videx®

• Dehydroepiandrosterone; DHEA; Prasterone; Dehydroisoandrosterone; EL- 10

• Dextran Sulfate • Dicaffeic acid ester; L-Chicoric acid

• DMP-266; Sustiva®; Efavirenz; Approved

• DMP-323; XM-323

• DMP-450

• Docosanol; n-Docosanol • dOTC (-); (-^'-Deoxy-S'-oxa^'-thiocytidine

• dOTFC (-); (-)-2'-Deoxy-3'-oxa-4^t-thio-5-fluorocytidine

• DP- 178; Pentafuside; T-20; GP41 127-162 AA; Enfuvirtide; Fuzeon®

• E-BPTU; HEPT deriv.; NSC 648400 • E-EBU; HEPT deriv.; MKC-442 deriv.

• E-EBU-dM; HEPT deriv.; MKC-442 deriv.

• E-EPSeU; HEPT deriv.; MKC-442 deriv.

• E-EPU; HEPT deriv.; MKC-442 deriv.

• Ebselen • Etoposide

• Epoxy steriod deriv.; (4α,5α,17β)-17-Hydroxy-3-oxo-4,5-epoxyandrostane-2-carboxamide

• Eulicin

• Fenalamide Al; Phenalamide Al; Stipiamide • Fleephilone

• Fluoroquinolone deriv.; K- 12

• Fortovase®; Invirase®; Saquinavir; Ro31-8959; Approved

• Foscarnet; Phosphonoformic acid; Foscavir; . FPMDAP; . FPMPA

• FPMPG

• GPGRAF Octomer; SPC3 • Hammerhead anti-gag RNA Ribozyme B

• Harziphilone

• HBY 097; Quinoxaline deriv. • HEPT deriv.; MKC-442 deriv.

• HEPT deriv.; MKC-442 deriv.

• HOCH2CH2 isostere; ThienopyridCON thienyl urethane deriv.

• HOCH2CH2 isostere; ThienopyridCON thienyl urethane deriv. • HOCH2CH2 isostere; ThienopyridCON thienyl urethane deriv.

• HOCH2CH2 isostere; ThienopyridCON thienyl urethane deriv.

• HOCH2CH2 isostere; ThienopyridCONthienyl urethane deriv.; LY326188

• HPMPA

• HPMPDAP • HU; Hydroxyurea; Hydrea

• Hydroxocobalamin

• Hypericin

• Ingenol 3,5,20-triacetate; ITA; RD3-2118 • Ingenol deriv.; RD4-2138

• Inophyllum B

• Inophyllum P

• iQoa-Mta-Apns-Thz-NH-tBu; KNI-272

• IsoquinCON furanyl urethane analog • IsoquinCON thienyl urethane analog

• IsoquinCON thienyl urethane analog

• KNI-154; Noa-Asn-Apns-Thz-NH-tBu

• KNI-174; Noa-Asn-Aρns-Dmt-NH-tBu • KNI-227; Qoa-Mta-Apns-Thz-NH-tBu

. L-685,434

• L-685,434-6-Hydroxy derivative

• L-685,434-OEtMorphderivative; L-689,502 • L-685,434-OEtNMe2

• L-685,434-OPrMorph derivative

• L-697,593; 2-Pyridinone deriv.

• L-697,639; 2-Pyridinone deriv. • L-697,661; 2-Pyridinone deriv.

• L-FddC; β-L-5F-ddC

• Lamivudine & Zidovudine; Combivir® 3TC & AZT; Approved

• LY289612

• LY289612 analog • LY289612 analog

. LY-300046-HC1; PETT deriv.; Trovirdine

• LY314163; Saquinavir/Nelfinavir deriv..

. LY-73497; N-(2-Phenethyl)-N^I-(2-thiazolyl)thiourea; PETT

• MAP; Methyl acetylenic putrescine

• Michellamine A; NSC650898 . Michellamine B; NSC649324

• Michellamine F

• N-6-Et-ddA; N-Ethyl-2',3'-dideoxyadenosine

• N-6-methyl ddA; N6-Methyl-2',3'-dideoxyadenosine

• Naphthalene 2-sulphonate polymer; PRO 2000

• Nelfinavir-octahydro-thienopyridine analog

• Nonoxynol 9 - NSC625487; Thiazolobenzimidazole; TBZ

• Oxathiin deriv.; UC-38

• Oxathiin deriv.; UC-84

. P9941

• Penicillin Et(NH)2 Sym dimer

• Penicillin G, ET(NH)2 deriv.

• Penicillin, 2Isoquin-OHPrNH2 analog • Penicillin, 2Isoquin-OHPrNH2 analog

• Pentosan Sulfate; Elrniron; SP54; Xylan Sulfate;

- PETT Cl, F deriv.

• PETT deriv. • PETT deriv.

• PETT deriv.

• Phenoxan

• Phorbol deriv.; Prostratin • Platanic acid

• PMEDAP

• PMEG

• PMEHx; PMEI

• PMEMAP • PMET

• PNU-140690; U-140690; Tipranavir

• Pyridinone deriv.

• Quinoxalin2thione deriv; S-2720

• R14458; TIBO deriv..

- R82150; TIBO deriv..

• R82913; TIBO deriv. • Resobene

• Ribavirin; Virazole

• Ro 31-8959-bis-thf deriv.

• Saquinavir/Nelfϊnavir deriv. • Saquinavir/Nelfinavir deriv.

• SB-205569; Val-Phe-Phe-HOCH2CH2 isostere analog

• SC-52151; Telinavir

• SDZ PRI 053

• Suramin Sodium • T22

• Thalidomide

• Thiangazole; (-)-Thiangazole • Thiazoloisoindol-5-one

• Thiazoloisoindol-5-one, deriv.

• Tle-Val-Sta, 5PhBuCOOH deriv.; Statine deriv.

• UC-781

• Val-Val-Sta, 5PhBuCOOH deriv.; Statine deriv.

• Val-Val-Sta, 5PhBuCOOH deriv.; Statine deriv. • Val-Val-Sta, 5PhBuCOOH deriv.; Statine deriv.

• Val-Val-Sta, 5PhBuCOOH deriv.; Statine deriv.

• VB-11,328

• Viread®; Tenofovir Disoproxil

An alternative list of drugs and/or bioactive agents useful in the treatment of HIV infections, or conditions or disease states which are secondary to HIV infections is set forth hereinbelow. One or more of these agents may be used in combination (coadminstered) with at least one diketo acid anti-HIV agent as otherwise disclosed herein to treat HIV or one of its secondary conditions or disease states, including AIDS/ARC, Kaposi's sarcoma, hepatitis B virus infections, other microbial infections (such as tuberculosis) etc. When used, these compounds are also included in effective amounts.

These include: ACV; AK602; AMD070; APV; ATV; ATZ; AVX754 (apricitabine); AZT; Abacavir; Abacavir / Lamivudine / Zidovudine; Abacavir sulfate; Abacavir sulfate/Lamivudine; Abacavir/Lamivudine; Abelecet; Acyclovir; Adefovir dipivoxil; Adriamycin; Agenerase; Aldesleukin; Alovudine; Aluvia; AmBisome; Amdoxovir; Amphocin; Amphotec; Amphotericin B; Ampligen; Amprenavir; Androderm; Androgel; Apricitabine; Aptivus; Atazanavir; Atripla; Azithromycin; BMS-378806; BMS-488043; Bactrim; Baraclude; Bevirimat; Biaxin; Brecanavir; BufferGel; C31G; CD4-IgG2; CS; CV- N; Calanolide A; Calcium hydroxylapatite; Carbopol 974P; Carrageenan; Carraguard;

Cellulose sulfate; Clarithromycin; Combivir; Copegus; Cotrimoxazole; Crixivan; Cyanovirin-

N; Cytovene; DAPD; DLV; DS; Darunavir; Delavirdine; Depo-Testosterone; Dextran sulfate; Didanosine; Diflucan; Doxil; Doxorubicin (liposomal); Dronabinol; EFV; Efavirenz; Elvucitabine; Emtricitabine; Tenofovir disoproxil fumarate; Emtriva; Enfufirtide; Entecavir;

Epivir; Epoetin alfa; Epogen; Epzicom; Etopophos (phosphate salt); Etoposide; Etravirine;

FTC; Fluconazole; Fortovase; Fosamprenavir; Foxivudine tidoxil; Fungizone; Fuzeon; GS

9137; GSK-873,140 (aplaviroc); GW433908; GW640385 (brecanavir); Ganciclovir;

Globulin, Immune; Growth hormone (human); Hepsera; Hivid; Human growth hormone; IL- 2; INH; Immune Globulin Intravenous (Human); Indinavir; Interferon alfa-2; Interleukin-2, recombinant human; Intron A (2b); Invirase; Isoniazid; Itraconazole; KP-1461;

Lamivudine/Zidovudine; Lexiva; Lopinavir/Ritonavir; MK-0518; Nebupent; Nelfinavir;

Neutrexin; Nevirapine; Norvir; Nydrazid; Peptide T; PMPA Prodrug (Viread)' Prezista

(Darunavir); PRO 140; PRO 2000; PRO 542 (CD4 IGg2); Procrit (Epoetin); Proleukin; Racivir; Radiesse; Rrebetol; Rescriptor; Retrovir; Reyataz; Ribavirin; Rifabutin; Rifadin;

Rifampin; Rimactane; Ritonavir; Roferon-A (2a); Saquinavir; SCH-D (vicriviroc);

Somatropin; Stavudinie; Sulfamethoxazole / Trimethoprim; Sustanon; Sustiva; TNX-355;

Taxol; Tenofovir; Tenofovir disoproxil fumarate; Testosterone; Tipranavir; Toposar;

Trimetrexate; Trizivir; Truvada (Emtriva and Viread combination); U-90152S (Delaviridine); UC-781 ; UK-427,857 (maraviroc); Valcyte; Valganciclovir; Valproic acid; VePesid;

Vicriviroc; Videx; Viracept (Tennofovir DF); Viramune; Virazole; Viread; Vitrasert;

Zalcitabine; Zerit; Ziagen; Zidovudine; Zithromax; Zovirax.

An alternative list of drugs and/or bϊoactive agents useful in the treatment of HIV infections, or conditions or disease states which are secondary to HIV infections is set forth hereinbelow. One or more of these agents may be used in combination (coadminstered) with at least one diketo acid anti-HIV agent as otherwise disclosed herein to treat HIV or one of its secondary conditions or disease states, including AIDS/ ARC, Kaposi's sarcoma, hepatitis B virus infections, other microbial infections (such as tuberculosis) etc. When used, these compounds are also included in effective amounts.

These include: ACV; AK602; AMD070; APV; ATV; ATZ; AVX754 (apricitabine); AZT; Abacavir; Abacavir / Lamivudine / Zidovudine; Abacavir sulfate; Abacavir sulfate/Lamivudine; Abacavir/Lamivudine; Abelecet; Acyclovir; Adefovir dipivoxil;

Adriamycin; Agenerase; Aldesleukin; Alovudine; Aluvia; AmBisome; Amdoxovir;

Amphocin; Amphotec; Amphotericin B; Ampligen; Amprenavir; Androderm; Androgel;

Apricitabine; Aptivus; Atazanavir; Atripla; Azithromycin; BMS-378806; BMS-488043; Bactrim; Baraclude; Bevirimat; Biaxin; Brecanavir; BufferGel; C31 G; CD4-IgG2; CS; CV-

N; Calanolide A; Calcium hydroxylapatite; Carbopol 974P; Carrageenan; Carraguard;

N; Cytovene; DAPD; DLV; DS; Darunavir; Delavirdine; Depo-Testosterone; Dextran sulfate; Didanosine; Diflucan; Doxil; Doxorubicin (liposomal); Dronabinol; EFV; Efavirenz; Elvucitabine; Emtricitabine; Emtricitabine;Tenofovir disoproxil fumarate; Emtriva;

Enfufirtide; Entecavir; Epivir; Epoetin alfa; Epogen; Epzicom; Etopophos (phosphate salt);

Etoposide; Etravirine; FTC; Fluconazole; Fortovase; Fosamprenavir; Foxivudine tidoxil;

Fungizone; Fuzeon; GS 9137; GSK-873,140 (aplaviroc); GW433908; GW640385

(brecanavir); Ganciclovir; Globulin, Immune; Growth hormone (human); Hepsera; Hivid; Human growth hormone; IL-2; INH; Immune Globulin Intravenous (Human); Indinavir;

Interferon alfa-2; Interleukin-2, recombinant human; Intron A (2b); Invirase; Isoniazid;

Itraconazole; KP-1461; Lamivudine/Zidovudine; Lexiva; Lopinavir/Ritonavir; MK-0518;

Nebupent; Nelfinavir; Neutrexin; Nevirapine; Norvir; Nydrazid; Peptide T; PMPA Prodrug

(Viread)' Prezista (Darunavir); PRO 140; PRO 2000; PRO 542 (CD4 IGg2); Procrit (Epoetin); Proleukin; Racivir; Radiesse; Rrebetol; Rescriptor; Retrovir; Reyataz; Ribavirin;

Rifabutin; Rifadin; Rifampin; Rimactane; Ritonavir; Roferon-A (2a); Saquinavir; SCH-D

(vicriviroc); Somatropin; Stavudinie; Sulfamethoxazole / Trimethoprim; Sustanon; Sustiva;

TNX-355; Taxol; Tenofovir; Tenofovir disoproxil fumarate; Testosterone; Tipranavir;

Toposar; Trimetrexate; Trizivir; Truvada (Emtriva and Viread combination); U-90152S (Delaviridine); UC-781 ; UK-427,857 (maraviroc); Valcyte; Valganciclovir; Valproic acid;

VePesid; Vicriviroc; Videx; Viracept (Tennofovir DF); Viramune; Virazole; Viread;

Vitrasert; Zalcitabine; Zerit; Ziagen; Zidovudine; Zithromax; Zovirax.

The following representative examples are provided to illustrate details for the preparation of the compounds of the present invention. The examples are not intended to be limitations on the scope of the present invention and they should not be so construed. Furthermore, the compounds described in the following examples are not to be viewed as forming the only set of compounds that is considered as the invention, and any combination of components of the compounds or their moieties may itself form a set. This has been addressed previously in this patent document. Those skilled in the art will readily comprehend that known variations of reaction conditions and synthetic conversions described in the following preparative procedures can be used to prepare these other compounds.

Chemical Synthesis

Representative Example 1

4-(l,5-dibenzyl~l,2-dihydro-2-oxopyridin-3-yl)-2-hydroxy-4-oxobut-2-enoic acid (8).

The relevant scheme (1) is shown below.

Scheme 1

Step 1 : 5-Benzylpyridin-2-amine (2).

A mixture of pyridine-2-amine 1 (14.1 g, 149.8 inmol) and benzylchloride (36.0 g, 284.6 mmol) was heated to 180 ⁰C until the mixture began to boil [Kowalski, J. Heterocycl. Chem. 28, 875 - 879 (1991)]. The temperature was then gradually raised during 3 h to 250 ⁰C and maintained for 24 h. After cooling, the reaction mixture was washed out from the flask with MeOH (60 mL) and treated with 10 % aqueous NH₄OH (40 mL). After addition of water (200 mL). the resulting oil was extracted with CHCI₃ (2 x 200 mL), dried over anhydrous Na₂SO₄, and CHCI₃ distilled off. The residue was separated by distillation under reduced pressure. The fraction collected at 130-135 °C/1 mm Hg was further purified by flash chromatography on silica gel (EtOAc:hexane, 7:3). Yield 9.2 g (34 %), white solid, mp 79-80 ⁰C. ¹H NMR (CDCl₃, 500 MHz): δ 3.87 (s, 2H, CH₂), 4.43 (bs, 2H, NH₂), 6.48 (d, IH, CH J= 8.5 Hz), 7.19-7.33 (m, 6H, Ar-H and CH), 7.99 (d, IH, CH, J= 1.5 Hz). ¹³C NMR (CDCl₃, 125 MHz): δ 38.2, 108.7, 126.1, 126.4, 128.5, 128.7, 128.9, 128.9, 138.6, 140.9, 147.7, 156.8.

Step 2: 5-Benzyl-3-bromopyridin-2-amine (3).

To a stirred solution of 5-benzylpyridin-2-amine 2 (6.0 g, 32.3 mmol) in CH₂Cl₂ (100 mL) cooled to 0 ⁰C was added bromine (5.1 g, 32.3 mmol) dropwise [Kelly, et al., J. Am. Chem. Soc. 112, 8024-8034 (1990)]. The bromine decolorized immediately and the mixture was left stirring for 30 min. The mixture was shaken with saturated NaHCθ₃ solution (100 mL), the organic layer was then dried over anhydrous Na₂SCU, and distilled off to give a yellow residue which was purified by flash chromatography on silica gel (EtOAc :hexane, 3:7). Yield 7.3 g (86 %), white solid, mp 110-111 ⁰C. ¹H NMR (CDCl₃, 500 MHz): δ 3.86 (s, 2H, CH₂), 4.88 (bs, 2H, NH₂), 7.19-7.35 (m, 5H, Ar-H), 7.50 (d, IH, CH, J= 1.5 Hz), 7.94 (d, IH, CH , J= 1.0 Hz). ¹³C NMR (CDCl₃, 125 MHz): δ 37.7, 104.6, 126.4, 126.4, 128.1, 128.6, 128.6, 128.7, 140.2, 140.8, 146.7, 154.0; HRMS (M + H)⁺ calcd for Cj₂H₁₃BrN₂ 263.0184, found 263.0184.

Step 3: 5-Benzyl-3-bromopyridin-2(iH)-one (4).

To a stirred solution of 5-benzyl-3-bromopyridin-2-amine 3 (0.2 g, 0.7 mmol) in

DMF (4 mL) was added water (2 drops) followed by /-butyl nitrite (0.378 g, 3.6 mmol) and the reaction mixture stirred at RT for 30 min. DMF and the excess reagent were distilled off, and the residue purified by flash chromatography on silica gel (EtOAc:hexane, 1:1). Yield 7.3 g (86 %), white solid, mp 151-152 ⁰C. ¹H NMR (CDCl₃. 500 MHz): δ 3.77 (s, 2H, CH₂), 7.17-7.36 (m, 6H, Ar-H and CH), 7.76 (d, IH, CH₅ J= 1.5 Hz) 13.25 (bs, IH, NH). ¹³C NMR (CDCl₃, 125 MHz): δ 37.3, 115.4, 121.0, 126.9, 128.8. 128.8, 128.9, 128.9, 132.4, 138.5, 145.3, 161.0; HRMS (M + H)⁺ calcd for C₁₂HnBrNO 264.0024, found 264.0014.

Step 4: l,5-Dibenzyl-3-bromopyridin-2(7H)-one (5).

To a suspension of 5-benzyl-3-bromopyridin-2(iH)-one 4 (3.5 g, 13.5 mmol) in dry DMF (100 mL) was added NaH 60 % suspension in mineral oil (0.5 g, 16.2 mmol) and stirred for 30 min, followed by the addition of benzyl bromide (0.1.36 g, 7.9 mmol) and mixture futher stirred for Ih at RT. DMF was distilled off and the residue redissolved in EtOAc (250 mL), washed with brine solution (2 x 100 mL), dried over anhydrous Na₂SO₄ and EtOAc distilled off to give a yellow syrup, which was purified by column chromatography on silica gel (EtOAc rHexane, 4:6) to give 5 . Yield 3.8 g (83 %), yellow solid, mp 89-90 ⁰C. ¹H NMR (CDCl₃, 500 MHz): δ 3.69 (s, 2H, CH₂), 5.18 (s, 2H, CH₂), 7.11 (d, IH, CH, J= 2 Hz), 7.12-7.39 (m, 1OH, Ar-H), 7.60 (d, IH, CH, J= 2 Hz), ¹³C NMR (CDCl₃, 125 MHz): δ 37.4, 53.5, 117.1, 119.1, 126.9, 128.2, 128.2, 128.3, 128.3, 128.6, 128.8, 128.8, 128.9, 128.9, 134.6, 135.8, 138.7, 143.0, 158.3. HRMS (M + H)⁺ calcd for C₁₉H₁₇BrNO 354.0494, found 354.0455.

Step 5: 3-Acetyl-l,5-dibenzyl-3-pyridin-2(iH)-one (6).

A mixture of l,5-dibenzyl-3-bromopyridin-2(7H)-one 5 (1.0 g, 2.8 mmol) bis(triphenylphosphine)palladium(II) chloride (0.19 g, 0.28 mmol) and ethoxyvinyl(tributyl)tin (2.03 g, 5.6 mmol) in dry DMF (50 mL) was heated under N₂ at 70 ⁰C for 1 h. DMF was distilled off and the resulting residue redissolved in EtOAc (50 mL) and filtered through a pad of celite EtOAc fraction was stirred with 1 N HCl (30 mL) for 15 min, washed with water (2 x 30 mL), and dried over anhydrous Na₂Sθ₄ and distilled off to give a yellow residue which was purified by flash chromatography on silica gel (EtOAc:hexane,2:8). Yield 0.86 g (97 %), yellow oil. ¹HNMR (CDCl₃, 500 MHz): δ 2.73 (s, 3H, CH₃), 3.75 (s, 2H, CH₂), 5.19 (s, 2H, CH₂), 7.14-7.40 (m, 1 IH, Ar-H and CH), 8.04 (d, IH, CH, J= 3 Hz). ¹³C NMR (CDCl₃, 125 MHz): δ 31.1, 37.5, 52.5, 118.6, 126.8, 127.8, 127.8, 127.9, 128.2, 128.2, 128.6, 128.6, 128.8, 128.8, 129.0, 135.8, 138.8, 140.7, 144.8, 160.4, 198.0; HRMS (M + H)⁺ calcd for C_2IH₂₀NO₂318.1494, found 318.1461.

Step 6: Methyl-4-(l,5-dibenzyl-l,2-dihydro-2-oxopyridin-3-yl)-2-hydroxy-4-oxobut-

2-enoate (J).

To a stirred solution of 3-acetyl-l,5-dibenzyl-3-pyridin-2(iH)-one 6 (0.1 g, 0.31 mmol) in THF (5 mL) was added Na-f-butoxide (0.30 g, 3.1 mmol) and the reaction mixture stirred for 15 min. A solution of dimethyl oxalate (0.37 g, 3.1 mmol) in THF (5 mL) was added at RT and stirred for 2 h. THF was distilled off and 1 N HCl (1 mL) was added and extracted with EtOAc (2 x 10 mL), washed with saturated brine solution (4 x 20 mL), dried over anhydrous sodium sulfate and EtOAc distilled off to give a brown residue which was purified first by ion exchange chromatography (Diethylamino sephadex anion exchange resin, (CH₃CN:H₂O, 1 :1) and then by flash chromatography on silica gel (CHCl₃:MeOH, 9.9:0.1). Yield 0.054 g (44 %), yellow oil. ¹HNMR (CDCl₃, 500 MHz): δ 3.79 (s, 2H₅ CH₂), 3.91 (s, 3H, CH₃), 5.21 (s, 2H, CH₂), 7.15-7.42 (m, HH, Ar-H and CH), 7.98 (s, IH, olefenic CH), 8.24(d, IH, CH, J= 2.5 Hz), ¹³C NMR (CDCl₃, 100 MHz): δ 37.5, 52.7, 53.0, 101.8, 119.0, 123.4, 126.9, 128.0, 128.0, 128.3, 128.6, 128.6, 128.9, 129.0, 129.0, 129.1, 135.6, 138.6, 141.4, 145.0, 159.5, 162.6, 172.2, 185.5; HRMS (M + H)⁺ calcd for C₂₄H₂₂NO₅ 404.1498, found 404.1411. Step 7: 4-(l,5-Diben2yl-l,2-dihydro-2-oxopyridin-3-yl)-2-hydroxy-4-oxobut-2-enoic acid (8).

To a stirred solution of methyl-4-(1.5-diben2yl-l,2-dihydro-2-oxopyridin-3-yl)-2- hydroxy-4-oxobut-2-enoate 7 (0.069 g, 0.17 mmol) in MeOH (5 mL) at 0 ⁰C was added a solution of IN NaOH (0.5 mL) and reaction mixture allowed to stir at 0 ⁰C for 30 min. Reaction was then allowed to stir at ambient temperature for 1 h. The reaction mixture was neutralized with 1 N HCl, the solid separated was filtered and dried under vaccum. Recrystallization with EtOAc/Hexane gave yellow solid. Yield 0.034 g (52 %), yellow solid, mp:158-159 ⁰C. ¹H NMR (CDCl₃ , 500 MHz): δ 3.82 (s, 2H, CH₂), 5.26 (s, 2H, CH₂), 7.16- 7.39 (m, 1OH, Ar-H), 7.45 (d, IH, CH, J= 2 Hz), 7.98 (s, IH, olefenic CH), 8.26 (d, IH, CH, J= 2 Hz), ¹³C NMR (CDCl₃, 125 MHz): δ 37.5, 53.3, 100.8, 119.8, 123.1, 127.0, 128.2, 128.5, 128.5, 128.6, 128.6, 128.9, 128.9, 129.0, 129.1, 129.1, 135.2, 138.4, 141.3, 145.1, 159.5, 162.3, 173.7; HRMS (M + H)⁺ calcd for C₂₃H₂₀NO₅390.1341, found 390.1342.

Representative Example 2

4-(l,5-dibenzyl-l,4-dihydro-4-oxopyridin-3-yl)-2-hydroxy-4-oxobut-2-enoic acid (16 ).

The relevant scheme (2) is shown below.

13 14

NaOBuVTHF MeOCOCOOMe

15 16

Scheme 2

Step 1 : 3,5-Dibromo-pyridin-4-one (10)

To an ice-cooled solution of pyridine-4-one 9 (6.98 g, 73.4 mmol) and KOH ( 9.52 g, 146.8 mmol) in water (140 mL) was added bromine (7.58 mL, 147.5 mmol) dropwise over 30 min [Spivey, et al., J. Org. Chem. 65, 3154-3159 (2000)]. After an additional 30 min, the precipitate was filtered off, washed with a copious amount of water, and dried in vacuo. Yield 16.17 g (87 %), yellow solid, mp 320 ⁰C (sublimes). ¹H NMR (OMSO-d₆, 500 MHz): δ 12.3 (s, IH), 8.26 (s, 2H). ¹³C NMR (DMSO-cfe, 125 MHz): δ 167.5, 138.2, 138.2, 111.8,111.8. Step 2: 3-Bromo-5-(hydroxy-ρhenyl-methyl)-pyridin-4-one (11)

To a heterogeneous mixture of 3,5-dibromo-pyridin-4-one 10 (0.313 g, 1.24 mmol) in anhydrous THF (4 mL) at -78 ⁰C under nitrogen atmosphere was added phenylmagnesium bromide solution (1.36 mL of 1 M solution in THF, 1.36 mmol) [Borzilleri, et al, US Pat. 20050245530], After stirring for 15 min, w-BuLi solution (0.68 mL of 2 M solution in cyclohexane, 1.36 mmol) was added and the reaction mixture stirred for 15 min at -78 ⁰C under nitrogen atmosphere. To this mixture was added benzaldehyde (0.26 mL, 2.6 mmol) and the mixture was stirred for 2 h at -78 ⁰C. The reaction mixture was quenched by adding HOAc (0.38 mL) and TFA (0.38 mL), concentrated in vacuo and the residue was purified by flash column chromatography on silica gel (dichloromethane: methanol, 95:5). Yield 0.125 g (36 %), white solid, 123-124 ⁰C. ¹H NMR (MeOH- d,, 500 MHz): δ 8.09 (s, IH), 7.81 (s, IH), 7.38-7.17 (m, 5H), 5.92 (s, IH), 3.83 (s, 2H). ¹³C NMR (MeOH- d₄, 125 MHz): δ 174.3, 144.4, 139.7, 135.8, 133.6, 129.4, 129.3, 128.6, 128.0, 128.0, 114.8, 70.8.

Step 3: 3-Berizyl-5-brornopyridin-4-one (12)

12

A mixture of 3-bromo-5-(hydroxyl-phenyl-methyl)pyridin-4-one 11 (0.125 g, 91 mmol), TFA (16 mL) and EtaSiH in anhydrous dichloromethane (30 mL) was stirred at rt for 1O h [Borzilleri, et al., US Pat. 20050245530]. The reaction mixture was concentrated in vacuo and the residue purified by flash column chromatography on silica gel (dichloromethane: methanol, 98:2). Yield 0.081 g (69 %), white solid. ¹H NMR (MeOH- d₄, 500 MHz): δ 8.12 (s, IH), 7.47 (s, IH), 7.29-7.17 (m, 5H), 3.83 (s, 2H). ¹³C NMR (MeOH- d₄, 125 MHz): δ 175.2, 140.7, 139.5, 136.9, 130.8, 130.0, 130.0, 129.5, 129.5, 127.3, 114.1, 34.9.

Step 4: l,3-Dibenzyl-5-bromo-l//-pyridin-4-one (13)

A mixture of 3-benzyl-5-bromopyridin-4-one 12 (0.57 g, 2.16 mmol) and NaOEt (

0.89 mL, 2.37 mmol) in absolute ethanol (20 mL) was refluxed with benzyl chloride ( 0.30 mL!, 2.59 mmol) for 1 h under nitrogen. The solvent was distilled off to give a yellow residue which was purified by flash column chromatography on silica gel (dichloromethane: methanol, 98:2). Yield 1.31 g (96.7 %), yellow solid, mp 120-121 ⁰C. ¹H NMR (CDCl₃, 500

MHz): δ 7.67 (d, IH, J= 2.4), 7.32-7.07 (m, 10H), 4.83 (s, IH), 3.78 (s, 2H). ¹³C NMR (CDCl₃, 125 MHz): δ 172.2, 139.6, 139.1, 137.6, 134.7, 129.9, 129.9, 129.3, 129.3, 129.2, 129.0, 128.6, 128.6, 127.5, 127.6, 126.4, 114.1, 60.3, 34.4. HRMS (M + H)⁺ calcd for Ci₉H₁₆BrNO 354.0494, found 354.0499.

Step 5: 3-Acetyl-l,5-dibenzyl-liJ-pyridin-4-one (14)

A mixture of l,3-dibenzyl-5-bromo-l//-pyridin-4-one 13 (1.31 g, 2.70 mmol), tributyl-(l-ethoxyvinyl)tin (1.80 mL, 5.18 mmol) and dichlorobis(triphenylphosphine)- palladium(II) (0.26 g, 0.37 mmol) in anhydrous DMF (20 mL) was stirred under nitrogen atmosphere at 95 ⁰C for 8 h. The reaction mixture was extracted with ethyl acetate (3 x 50 mL), washed with IN HCl (3 x 50 mL), and solvent distilled off. The residue was purified by flash column chromatography on silica gel (dichloromethane: methanol, 98:2). Yield 1.06 g (90 %), yellow oil. ¹H NMR (CDCl₃, 500 MHz): δ 8.19 (d, IH₅ J=2.6), 7.39-7.10 (m, 10H), 6.90 (d, IH, J=2.5), 4.89 (s, 2H), 3.81 (s, 2H), 2.74 (s, 3H). HRMS (M + H)⁺ calcd for C₂IH₁₉NO₂ 318.1494, found 318.1493.

Step 6: Methyl 4-(l,5-dibenzyl-4-oxo-l,4-dihydro-pyridin-3-yl)-2-hydroxy-4-oxo- but-2-enoate (15).

To a stirred solution of sodium ?-butoxide (0.52 g, 5.23 mmol) in anhydrous THF (13 mL) at room temperature was added dropwise dimethyl oxalate (0.42 g, 3.48 mmol) in THF (6 mL) followed by 3-acetyl-l,5-dibenzyl-l//-pyridin-4-one 14 (0.55 g, 1.74 mmol) in THF (8 mL). The resulting mixture was stirred at room temperature for 4 h and then acidified (pH = 6). The crude product was extracted with ethyl acetate (100 mL), washed with water (2 x 100 mL) and brine (2 x 100 mL), and dried over anhydrous sodium sulfate and the solvent was distilled off. The residue was purified by ion exchange chromatography (diethylamino sephadex anion exchange resin (CH₃CN: H₂O, 1:1) and then by flash chromatography on silica gel (chloroform, 100 %). Yield 0.44 g (63 %), mp 148-150 ⁰C. ¹H NMR (CDCl_3, 500 MHz): δ 8.34 (d, J= 2.5, IH), 8.12 (s, IH), 7.40-7.12 (m, 10H), 6.91 (d, J= 2.3, IH), 4.94 (s, 2H), 3.88 (s, 3H), 3.82 (s, 2H). ¹³C NMR (CDCl₃, 125 MHz): δ 187.2, 175.2, 170.3, 162.7, 143.9, 138.4, 136.9, 136.1, 133.8, 129.4, 129.5, 129.3, 129.1, 129.1, 128.7, 128.6, 127.5, 127.4, 126.5, 120.2, 102.4, 61.2, 53.0, 33.5. HRMS (M + H)⁺ calcd for C₂₄H₂₂NOs 404.1498, found 404.1497.

Step 7: 4-(l,5-dibenzyl-l,4-dihydro-4-oxopyridin-3-yl)-2-hydroxy-4-oxobut-2-enoic acid (16 ).

A mixture of methyl-4-(l,5-dibenzyl-l,4-dihydro-4-oxopyridin-3-yl)-2-hydroxy-4- oxobut-2-enoate 15, (0.080 g, 0.19 mmol) and 1 N NaOH (4 mL) in THF (12 mL) was stirred at 0 ⁰C for 4 h. THF was distilled off and the residue acidified with 1 N HCl and extracted with EtOAc (2 x 25 mL), washed with brine solution (1 x 25 mL). dried over anhydrous Na₂SO4 and EtOAc distilled off to give a yellow solid. The crude solid was triturated with diethylether, filtered and dried under vaccum. Finally the solid was triturated with chloroform, filtered and dried under vaccum for 24 h. Yield 0.065 g (84 %), yellow solid, mp 140-142 ⁰C. ¹H NMR (CDCl₃ + MeOH-d₄, 500 MHz): δ 3.80 (s, 2H, CH₂), 4.97 (s, 2H, CH₂), 6.95 (t, IH, CH, J= 1 Hz), 7.13-7.40 (m, HH, Ar-H and olefenic CH), 8.36 (d, IH, CH, J= 2.5 Hz). ¹³C NMR (CDCl₃, 125 MHz): δ 33.4, 61.2, 120.5, 126.5, 127.5, 127.6, 128.6, 128.7, 128.7, 129.1, 129.1, 129.2, 129.2, 129.2, 129.4, 133.8, 135.9, 137.2, 138.2, 143.8, 163.8, 175.4. HRMS (M + H)⁺ calcd for C₂₃H₂₀NO₅ 390.1341, found 390.1343.

Claims

We claim:

1. A compound according to the general structure of formula I:

I wherein the scaffold is independently the 2- and 4-pyridinones identified herein and their regioisomers;

R¹ and R² are each independently H, Ci_s alkyl,

fluoroalkyl, unsubstituted or substituted C5-₆ cycloalkyl, C₁^ alkenyl, unsubstituted or substituted phenyl, unsubstituted or substituted benzyl, C2.₆ alkyl phenyl which phenyl moiety may be optionally substituted, unsubstituted or substituted heteroaryl, C ₁-₆ alkyl substituted with a heteroaryl group which heteroaryl group is optionally substituted, Ci-e alkyl S(O)R or alkyl (SC^)R where R is alkyl, phenyl or substituted phenyl, Ci_-6 alkyl CO₂R^a where R^a is Ci_-6 alkyl or H, Ci_-6 alkyl COR^a> where R^a is Ci-₆ alkyl;

R³ and R⁴ are independently selected from H, Ci^ alkyl, halogen, hydroxyl, unsubstituted or substituted benzyl, or unsubstituted or substituted phenylthio;

R⁵ is CO₂R⁰ or P(O)(OR°)(OR^C), where each R^c is independently from H and Ci-₆ alkyl,

Or a pharmaceutically acceptable salt thereof.

2. A compound of claim 1 according to the structure:

wherein R¹ and R² are each independently a benzyl group or a substituted benzyl group with 1 to 3 substituents on the aromatic ring selected from halogen, hydroxyl. methoxy, methyl, ethyl, propyl, CF_{3 ,} or a -CH₂ R^b group where R^b is a 5- or 6-membered heteroaryl group;

R³ and R⁴ are independently H, C]_-6 alkyl, halogen, benzyl, substituted benzyl, phenylthio, or substituted phenylthio with 1 to 3 substitutents on the phenyl ring selected from halogen, hydroxyl, methoxy, methyl, ethyl, propyl, CF₃; wherein R⁵ is CO2R where R is selected from H and C^ alkyl, or a pharmaceutically acceptable salt thereof.

3. The compound of claim 1 according to the structure:

wherein R¹ and R² are each independently a benzyl group or substituted benzyl group with 1 to 3 substituents on the aromatic ring selected from halogen, hydroxyl, methoxy, methyl, ethyl, propyl, CF₃ or wherein R¹ and R² are independently -CH₂R¹³ where R is a 5- or 6-membered heteroaromatic ring; wherein R³ and R⁴ are independently H, Ci-₆ alkyl, halogen, benzyl, substituted benzyl, phenylthio, or substituted phenylthio with 1 to 3 substitutents on the phenyl ring selected from halogen, methoxy, methyl, ethyl, propyl, CF₃; wherein R⁵ is P(O)(OR)(OR), where the R groups could be the same or not and are selected from H or Ci_5 alkyl, or a pharmaceutically acceptable salt thereof.

4. A compound of claim 1 according to the structure:

wherein R¹ and R² are each independently a benzyl group or a substituted benzyl group with 1 to 3 substituents on the aromatic ring selected from halogen, hydroxyl, methoxy, methyl, ethyl, propyl, CF₃ , or a -CH₂ R^b group where R^b is a 5- or 6-membered heteroaryl group;

R³ and R⁴ are independently H, Ci-β alkyl, halogen, benzyl, substituted benzyl, phenylthio, or substituted phenylthio with 1 to 3 substitutents on the phenyl ring selected from halogen, hydroxy 1, methoxy, methyl, ethyl, propyl, CF₃; wherein R⁵ is CO₂R where R is selected from H and Ci-6 alkyl, or a pharmaceutically acceptable salt thereof.

5. A compound of claim 1 according to the structure:

O O OH

R² wherein R¹ and R² are each independently a benzyl group or substituted benzyl group with 1 to 3 substituents on the aromatic ring selected from halogen, hydroxyl, methoxy, methyl, ethyl, propyl, CF₃ or wherein R¹ and R² are independently -CH₂R¹⁵ where R^b is a 5- or 6-membered heteroaromatic ring; wherein R³ and R⁴ are independently H, Ci-β alkyl, halogen, benzyl, substituted benzyl, phenylthio, or substituted phenylthio with 1 to 3 substitutents on the phenyl ring selected from halogen, methoxy, methyl, ethyl, propyl, CF_3; wherein R⁵ is P(O)(OR)(OR), where the R groups could be the same or not and are selected from H or C₁ -₆ alkyl, or a pharmaceutically acceptable salt thereof.

6. A compound of claim 1 selected from the group consisting of 4-(l,5-dibenzyl-l,2-dihydro-2-oxopyridin-3-yl)-2-hydroxy-4-oxobut-2-enoic acid; 4-(l,5-dibenzyl-l,4-dihydro-4-oxopyridin-3-yl)-2-hydroxy-4-oxobut-2-enoic acid;

3-Acetyl-l,5-dibenzyl-3-pyridin-2(7H)-one;

3-Aceryl-l,5-dibenzyl-l-?-r-pyridin-4-one;

Methyl-4-(l,5-dibenzyl-l,2-dihydro-2-oxopyridin-3-yl)-2-hydroxy-4-oxobut-2- enoate; and Methyl 4-(l,5-dibenzyl-4-oxo-l,4-dihydro-pyridin-3-yl)-2-hydroxy-4-oxo-but-2- enoate, or a pharmaceutically acceptable salt thereof.

7. A compound according to claim 1 selected from the group consisting of

4-( 1 ,5-dibenzyl- 1 ,2-dihydro-2-oxopyridin-3-yl)-2-hydroxy-4-oxobut-2-enoic acid; and

4-( 1 ,5-dibenzyl- 1 ,4-dihydro-4-oxopyridin-3-yl)-2-hydroxy-4-oxobut-2-enoic acid, or a pharmaceutically acceptable salt thereof.

8. A compound according to claim 1 according to the structure:

wherein R¹ and R² are independently benzyl groups or substituted benzyl groups with 1 to 3 substituents on the phenyl rings selected from the group consisting of fluorine, chlorine, C 1-4 alkyl, C2-₄ alkenyl and methoxy; R³ is H, C₁.₃ alkyl, C₂-₃ alkenyl, fluorine, chlorine or methoxy; R⁴ is H, F, Cl or OH; and

R⁵ is CO₂H or P(O)(OH)_{2 ,} or a pharmaceutically acceptable salt thereof.

9. The compound according to claim 1 wherein at least one of R¹ and R² is a benzyl group.

10. The compound according to claim 1 wherein both R¹ and R² are benzyl groups.

11. The compound according to claim 8 wherein both R¹ and R² are benzyl groups.

12. The compound according to any of claims 1-5 and 8-11 wherein R and R⁴ are independently H, methyl, fluorine or chlorine.

13. The compound according to any of claims 1-5 amd 8-12 wherein R³ and R⁴ are independently H, fluorine or chlorine.

14. The compound according to any of claims 1-5 and 8-13 wherein R³ and R⁴ are each H.

15. The compound according to claim any of claims 1-5 and 8-14 wherein R⁵ is CO₂H or a pharmaceutically acceptable salt thereof.

16. A pharmaceutical composition comprising a therapeutically effective amount of a compound according to any of claims 1-15 and a pharmaceutically acceptable carrier, additive or excipient.

17. The pharmaceutical composition of claim 16 wherein said composition inhibits HIV integrase, both wild type and mutants, in a human host.

18. A pharmaceutical composition comprising a therapeutically effective amount of a first compound according to any of claims 1-15 in combination with a therapeutically effective amount of at least one additional compound selected from the group consisting of i) an additional anti-HTV agent, ii) an anti-infective agent other than an anti-HTV agent, iii) an immunomodulator, iv) other combination agent selected from the table shown on pages 17- 28, herein, and a pharmaceutically acceptable carrier, additive or excipient.

19. The composition according to claim 18 wherein said anti-infective agent is an antiviral agent selected from the group consisting of a protease inhibitor, a reverse transcriptase inhibitor, an additional integrase inhibitor or a combination thereof.

20. The composition of claim 19 wherein said reverse transcriptase inhibitor is a nucleoside compound.

21. The composition of claim 19 wherein said reverse transcriptase inhibitor is a non- nucleoside compound.

22. The composition of claim 19 wherein the said additional integrase inhibitor is a compound other than a pyrimidinone compound.

23. The composition according to any of claim 16-22 in oral or parenteral dosage form.

24. The composition according to any of claims 16-22 formulated for administration as an inhalation spray or a rectal suppository.

25. A method of preparing a pharmaceutical composition comprising combining a compound of any of claims 1-15 with a pharmaceutically-acceptable carrier, additive or excipient to produce a mixture and preparing an oral or parenteral dosage form from said mixture.

26. A method of treating an HIV infection in a patient, said method comprising administering to said patient an effective amount of a composition according to any of claims 16-24 to said patient.

27. A method of reducing the likelihood of an HIV infection in a patient at risk for said infection, said method comprising administering to said patient an effective amount of a composition according to any of claims 16-24 to said patient.

28. A method of treating a patient with AIDS or ARC comprising administering to said patient a therapeutically effective amount of a composition according to any of claims

16-24.

29. A method of inhibiting HIV integrase in a subject, said method comprising administering to said subject a therapeutically effective amount of a composition according to any of claims 16-24 to said subject.

30. The method according to any of claims 26-29 wherein said subject is a human.

31. The method according to any of the claims 26-30 wherein said anti-HIV or other agent is a compound which is set forth in the table on any of pages 17-28, herein.

32. A method of treating an HIV infection in a human host comprising administering to said host the composition of claim 27.

33. The method according to claim 32 wherein said composition comprises an effective amount of the compound

34. A pharmaceutical composition comprising an effective amount of a first compound according to any of claims 1-15 in combination with an effective amount of at least one anti-HIV or other compound which is set forth in the table on any of pages 17-28, herein, in combination with a pharmaceutically acceptable carrier, additive or excipient.

35. The pharmaceutical composition according to claim 16, 18 or 34 wherein said compound is

36. A pharmaceutical composition according to claim 16 further comprising at least one additional compound is selected from the group consisting of (-)β-Dioxolane-G (DXG); (-)β-Arctigenin (Arctigenin); (-)-Carbovir (-)-C-D4G; OO^S'-Dideoxy-S-fluoro-S¹- thiacytidine (FTC); (-)-β-D-2,6-Diaminopurine dioxolane (DAPD); (+)-2'-Deoxy-3'-oxa-4'- thiocytidine (dOTC +); (+)-2^l-Deoxy-3'-oxa-4'-thio-5-fluorocytidine (dOTFC +); (+/-)-

Lobucavir;

(R)-2QuinCOAsnPhe[CHOHCH2]PipCONHtBu; (R)-3,6-Diamino-N- (aminomethyl)hexanamide (Bellenamine); (R)-9-(2-Phosphonylmethoxypropyl)adenine

(Tenofovir); (R)-PMPDAP; (S)-9-(2-Phosphonylmethoxypropyl)adenine ((S)-PMPA);

PMPA(S); α-APA (Loviride); R87232; R88703; α-APA enantiomer (R90385); α-LτAZT; α-L-Dioxalane-C (α-L-DXC); α-L-FTC; α-Monofluoromethyldehydroornithine methyl ester (MFMOME); 1 , 1 '- Azobisformamide (ADA); 1-(1 l-Octylamino-10-hydroxjαιndecyl)-3,7-dimethylxanthine (CT-2576);

1 -(2',3 ^l-Dideoxy-2'-fluoro-β-D-threo-pentofuranosyl)cytosine (Ro 31 -6840); l-(2^l-Fluoro-2^3^I-dideoxy-β-D-e^ytihLro-pentofu^anosyl)thymine (2'FddT); l-[(2-Hydroxyethoxy)methyl]-6-(3-methylρhenyl)thio)thymine (HEPT-M);

1 -[(2-Hydroxyethoxy)metliyl]-6-(phenylthio)-2-thiothyinine (HEPT-S); 1 -[(2-Hydroxyethoxy)methyl] -6-(ρhenylthio)thymine (HEPT);

Deoxynojirimycin (1-Deoxynojirimycin); Amprenavir; Abacavir Succinate(Ziagen); 1-

Aminooxyethylamine (AEA); l-Methoxyoxalyl-3,5-dicaffeoylquinic acid (l-MO-3.5-

DCQA); 10H-2(Cbz-Tle)3PhPr [14]paracyclophane deriv; 10H-2(Cbz-ValNH)3PhPr

[13]metacyclophane deriv.; 10H-2(Cbz-ValNH)3PhPr [13]paracyclophane deriv.; lOH-2(Cbz-ValNH)3PhPr [14]paracyclophane deriv.; 10H-2(Cbz-ValNH)3PhPr

[17]paracyclophane deriv.; 12-Deoxyphorbol-13-(3E,5E-decadienoate); lό.alpha.-

Bromoepiandrosterone (Epi-Br) or (Inactivin); l-β-D-arabinofuranosyl-5-(2- bromovinyl)uracil (Sorivudine); 2',3'-Didehydro-3'-deoxycytidine (D4C);

2'.3'-Dideoxydidehydroguanosine (D4G); 2',3'-Didehydro-3'-deoxythymidine (D4T) (Stavudine); 2^I,3'-Dideoxy-3^l-fluoro-4-thiothymidine (3'-F-4-Thio-ddT);

2^l,3'-Dideoxy-3'-fluoro-5-bromouridine (FddBrU); 2^t,3'-Dideoxy-3'-fluoro-5-chlorocytidine

(3'-F-5-Cl-ddC); 2',3^l-Dideoxy-3'-fluoro-5-chlorouridine (935U83) (Raluridine); 2',3'-

Dideoxy-5-ethylcytidine (5-Et-ddC); 2',3'-Dideoxyadenosine (ddA);

2',3'-Dideoxydidehydroadenosine (d4A); 2',3 -Dideoxyguanosine (ddG); 2^I,3'-Dideoxy-3^l-hydroxymethyl cytidine (3'-Hydroxymethyl-ddC); 2,5'-Anhydro-3^r-azido-

2',3'-dideoxyuridine (AZU-2,5'-anhydτo); 2,5'-Anhydro-3'-azido-3^l-deoxythymidine (AZT-

2,5'-anhydτo); 2',5'diSilySpiroT (TSAO-T); 2',5'diSilySpiroT (TSAO-me^Λ3T); 2,6-Diamino-2',3^I-dideoxypurine-9-ribofuranoside (ddDAPR)( 2,6- Diamino-ddP); 2,6-Diaminopurine- 2^f,3'-dideoxydidehydroriboside (ddeDAPR); 2,6- Diaminopurine-S'-fluoro^'.S'-dideoxyriboside (3'-F-ddDAPR); 2-Aminobenzylstatine Valyl Cbz deriv; 2-Glycine amide-5-chlorophenyl 2-pyτryl ketone (GCPK); [2- PyridCH2NCH3CO-Val-NHCH(Bz)]CHOHCHOH (A-77003); 2'-Azido-2',3^l- dideoxyadenosine (2'-N3ddA); 2'-F-dd-aτa-A (Lodensine); 2*-FddT ; 2'-N3ddA; 2'-N3ddA (β- D-threo); 2-NaphCOAsnPhe[CHOHCH2]Pro-OtBu; 2-Nitrophenylphenylsulfone (NPPS); 3- (3-Oxo-l-propenyl)-3'-azido-3'-deoxythymidine (3-(3-Oxo-l-propenyl)AZT); 3-(3-Oxo-l- propenyl)AZT; L-737,126; 3,5-Dicaffeoylquinic acid (3,5-DCQA); 3'-Azido-3'-deoxy-6- azathymidine; 3*-Azido-2',3^l-dideoxy-5-[(cyanomethyl)oxy]uridine; 3 '- Azido-2',3 '-dideoxy-5- aminouridine; 3 '-Azido-2',3 '-dideoxy-5-aza-6-deazauridine; 3'-Azido-2',3'-dideoxy-5- bromouridine; 3'-Azido-2^l,3'-dideoxy-5-chlorocytidine (3'-Az-5-Cl-ddC); 3'-Azido-2',3'- dideoxy-S-dimethylarainouridine^'-Azido^'^'-dideoxy-S-ethyluridine; 3'-Azido-2',3'- dideoxy-5-fluorocytidine; S'-Azido^'^'-dideoxy-S-fluoroviridine; 3'-Azido-2',3'-dideoxy-5- hydroxyuridine; 3'-Azido-2',3'-dideoxy-5-iodouridine; 3'-Azido-2',3'-dideoxy-5- methyaminouridine; 3^r-Azido-2',3'-dideoxy-5-methylcytidine; 3'-Azido-2',3'-dideoxy-5- thiocyanatouridine; 3'-Azido-2',3'-dideoxy-5-trifluoromethyluridine; 3'-Azido-2',3'- dideoxycytidine; 3¹- Azido-2',3 '-dideoxyguanosine; 3 '-Azido-2',3 '-dideoxy-N4— 5- dimethylcytidine; 3^l-Azido-2',3'-dideoxy-N4-OH-5-metb.ylcytidine; 3^I-Azido-2',3¹- dideoxyuridine (Uravidine); 3'-Azido-3'-deoxy-6-azathymidine; 3-Azido-3'-deoxythymidilyl- (S'^O^'.S'-dideoxy-S'-adenylic acidj S'-Azido-S'-deoxythymidilylKS'^O^'^'-dideoxy-S¹- adenylic acid, 2-cyanoethyl ester; 3'-Azido-3'-deoxythymidilyl-(5^l,5^l)-2',3'-dideoxy-5^l- inosinic acid (AZT-P-ddl); 3'-Azido-3'-deoxythymidine-5'-(butylmethoxyvalinyl)phosphate; 3'-Azido-5-chloro-2',3'-dideoxyuridine; 3'-Deoxythymidine (ddT); 9-(3'-Fluoro-2',3'-dideoxy- β-D-erythropentafuranosyl)adenine;

S'-Fluoro^S'-dideoxy-S-iodouridine (FddIU); S'-Fluoro^'^'-dideoxycytidine (3'-FddC); 3'- Fluoro-2',3'-dideoxyguanosine (3'-FddG); 3 '-Fluoro-2',3 '-dideoxyuridine (3'-FddU); 9-(3'- Azido^'^'-dideoxy-β-D-erythropentafuranosyOadenine; 3TC (Lamivudine); 3TC & AZT (Combivir); 4'-Acetoamidophenyl4-guadinobenzoate; 4'-Azido-3'-deoxythymidine; 4'-Azido- 5-chloro-2'-deoxyuridine; 4'-Azido-2'-deoxyadenosine; 4'-Azido-2'-deoxycytidine; 4'-Azido- 2'-deoxyguanosine; 4'-Azido-2'-deoxyinosine; 4'-Azido-2'-deoxyuridine; 4'-Azidothymidine; 4'-Cyanothymidine; 4-Methyl-5-(pyrazinyl)-3H-l,2-dithiole-3-thione (Oltipraz); 5'-[(l,4- Dihydro-l-methyl-S-pyridinylcarbonyOoxyj-S'-azido^'_jS'-deoxythyπύdine (DP-AZT); 5'- [[(Z)-4-amino-2-butenyl]methylainino]-5'-deoxyadenosine (MDL 73811); 5¹- Alkylglycosidecarbonate of 3'-azido-3'-deoxyihymidine; 5C13PhS-2IndolCONH2; 5-Fluoro- 2',3'-dideoxycytidine; 5-Methyl-3^!-a2ido-2',3'-dideoxyisocytidine; Celgosivir; 6-Chloro-9- (2,3-dideoxy-β-D-glyceropentofuranosyl)-9H-purine; 6-Dimethylaminopurine-2'₅3'- dideoxyriboside; Ro 24-7429; Ro 5-3335; Tivirapine; 9-(2,3-Dideoxy-β-D-ribofuranosyl)-6- (methylthio)purine; 9-(2'-Azido-2',3 '-dideoxy-B-D-threopentafuranosyl)adenine; C- oxetanocin A; (+-)Lobucavir; A-76890; A-77003; A-77212; A-80987; A-81525; A-83962; A-98881; PNU-104489; Trizivir; Lopinavir; Kaletra; Lopinavir & Ritonavir; Aluviran^® & Norvir; Azodicarbonamide; Adefovir; Adefovir dipivoxil (Preveon®); Nelfinavir; AGl 350 (LY316957); R-87366; Alpha-lipoic acid; Alovudine (3'-FddT); ALX40-4C; AMD3100

(JM3100); Amdoxovir (APD); Amprenavir phosphate (Fosamprenavir); Ancer 20 (Z-100); Atazanavir (Latazanavir); Atevirdine; Aurintricarboxylic acid; AY 9944; 3'-Azido-5-chloro- 2',3'-dideoxyuridine; AZT; α-L-AZT; O,O'-Bis(3'-azido-3'-deoxythymidin-5'- yl)methylphosphonate; Baicalin (TJN-151); Betulinic acid (Mairin); Betulinic acid, 3-O- (3',3'-dimethylsuccinate); Delavirdine (U-90152); U-88204E; Nevirapine; BILA 1906 BS; BILA 2011 BS (Palinavir); BILA 2185 BS; NSC633001; CGP 53820; bis-ValHOEt-N2aza- peptide isostere (CGP 53820 analog); BMS-186318; L-687,908; Brovavir; BzOCValPhe[diCHOH(RR)]PheValBzOC; BzOCValPhe[diCHOH(SS)]PheValBzOC; C2- Sym Phosphinic amide deriv. (HOECHST AG);NSC675451; Calanolide B; Capravirine (S- 1153); Carbovir; Castanospermine; CGP 61755 (Lasinavir); CGP 64222; CNI-H0294;

Emivirine; Conocurvone (NSC650891); Emtricitabine; C-Oxetanocin-G; Indinavir; Curdlan Sulfate; Cyanovirin-N ; SD146; Cyclosporin A; SDZNIM 811; L-^^'-Didehydro^'^'- dideoxyadenosine (L-D4A); 2^l,3^l-Didehydro-2',3'-dideoxy-5-fluorocytidine (DD4C); L-2',3'- Didehydro-2'_:,3^l-dideoxy-5-fluorocytidine (LD4C); L-2',3^I-Didehydro-2',3'-dideoxyguanosine (LD4G) ; L^'^'-Didehydro^'^'-dideoxyinosine (LD4I); DABO; ddl; ddC; DMP-323; DMP- 450; (-)-2'-Deoxy-3'-oxa-4'-tbiocytidine; (^^'-Deoxy-S'-oxa-^-thio-S-fiuorocytidine ; Pentafuside (Enfuvirtide); Etoposide; Efavireπz; Emtriva; K- 12 (fluoroquinoline derivative); Saquinavir; Foscarnet; Phosphonoformic acid; Foscavir; FPMDAP; FPMPA; FPMPG; Gene Expression Modulator 91 (GEM91); Hammerhead anti-gag RNA Ribozyme B; Harziphilone; HBY 097 (Quinoxaline deriv); E-EBU; E-EPSeU; E-EPU; NSC 648400; E-EBU-dM; Zalcitabine; LY326188; Ingenol 3,5,20-tdacetate (ITA); Inophyllum B; KNI-272; RD3- 2118; KNI-102; KNI-154; KNI-174; KNI-227; L-685,434; L-689,502; L-697,593; L- 697,639; L-697,661; LY289612; Trovirdine; LY-73497; L-735,524; N-Ethyl-^.S¹- dideoxyadenosine; N6-Methyl-2',3'-dideoxyadenosine; Noa-Asn-Apns-Thz-NH-tBu;

Nonoxynol 9; Ritonavir; NSC625487; NSC649324; NSC650898; UC-38; UC-84; P9941;

Palinavir; Pentosan Sulfate; Elmiron; SP54; PNU-140690 (Tipranavir); S-2720; R14458;

R82150; R82913; R86183; RD4-2138; Resobene; Reyataz; Ribavirin; 7-Chloro-N-methyl-5- (lH-pyiτol-2-yl)-3H-l,4-benzodiazepin-2-aπcdne; 7-Chloro-5-(2-pvrryl)-3H-l,4- benzodiazepin-2(H)-one; LY314163; SB-205569; Telinavir; SD-095345SD146; SDZ PRI

053; SPC3; Suramin Sodium; T22; Thalidomide; Thiangazole; Thiazoloisoindol-5-one; U-

104489; U-140690; U-87201E; U-88204E; UC-781; VB-11,328; VX-478; 141W94; XM-323 and mixtures thereof.

37. The composition according to claim 16 further comprising an additional compound selected from the group consisting of ACV; AK602; AMD070; APV; ATV; ATZ;

AVX754 (apricitabine); AZT; Abacavir; Abacavir / Lamivudine / Zidovudine; Abacavir sulfate; Abacavir sulfate/Lamivudine; Abacavir/Lamivudine; Abelecet; Acyclovir; Adefovir dipivoxil; Adriamycin; Agenerase; Aldesleukin; Alovudine; Aluvia; AmBisome; Amdoxovir;

Amphocin; Amphotec; Amphotericin B; Ampligen; Amprenavir; Androderm; Androgel;

Apricitabine; Aptivus; Atazanavir; Atripla; Azithromycin; BMS-378806; BMS-488043;

Bactrim; Baraclude; Bevirimat; Biaxin; Brecanavir; BufferGel; C31G; CD4-IgG2; CS; CV-

N; Calanolide A; Calcium hydroxylapatite; Carbopol 974P; Carrageenan; Carraguard; Cellulose sulfate; Clarithromycin; Combivir; Copegus; Cotrimoxazole; Crixivan; Cyanovirin-

N; Cytovene; DAPD; DLV; DS; Darunavir; Delavirdine; Depo-Testosterone; Dextran sulfate; Didanosine; Diflucan; Doxil; Doxorubicin (liposomal); Dronabinol; EFV; Efavirenz;

Elvucitabine; Emtricitabine; Tenofovir disoproxil fumarate; Emtriva; Enfufήtide; Entecavir;

Epivir; Epoetin alfa; Epogen; Epzicom; Etopophos (phosphate salt); Etoposide; Etravirine; FTC; Fluconazole; Fortovase; Fosamprenavir; Foxivudine tidoxil; Fungizone; Fuzeon; GS

9137; GSK-873,140 (aplaviroc); GW433908; GW640385 (brecanavir); Ganciclovir;

Globulin, Immune; Growth hormone (human); Hepsera; Hivid; Human growth hormone; IL-

2; DSfH; Immune Globulin Intravenous (Human); Indinavir; Interferon alfa-2; Interleukin-2, recombinant human; Intron A (2b); Invirase; Isoniazid; Itraconazole; KP-1461; Lamivudine/Zidovudine; Lexiva; Lopinavir/Ritonavir; MK-0518; Nebupent; Nelfinavir;

(Darunavir); PRO 140; PRO 2000; PRO 542 (CD4 IGg2); Procrit (Epoetin); Proleukin;

Racivir; Radiesse; Rrebetol; Rescriptor; Retrovir; Reyataz; Ribavirin; Rifabutin; Rifadin;

Rifampin; Rimactane; Ritonavir; Roferon-A (2a); Saquinavir; SCH-D (vicriviroc); Somatropin; Stavudinie; Sulfamethoxazole / Trimethoprim; Sustanon; Sustiva; TNX-355; Taxol; Tenofovir; Tenofovir disoproxil fumarate; Testosterone; Tipranavir; Toposar; Trimetrexate; Trizivir; Truvada (Emtriva and Viread combination); U-90152S (Delaviridine); UC-781; UK-427,857 (maraviroc); Valcyte; Valganciclovir; Valproic acid; VePesid; Vicriviroc; Videx; Viracept (Tennofovir DF); Viramune; Virazole; Viread; Vitrasert; Zalcitabine; Zerit; Ziagen; Zidovudine; Zithromax; Zovirax and mixtures thereof.

38. The composition according to any of claims 34-37 wherein said composition treats said HIV infection by inhibiting at least HIV integrase, both wild type and mutants, in the human host.

39. The composition according to any of claims 34-38 in oral or parenteral dosage form.

40. The composition according to any of claims 34-38 formulated for administration as an inhalation spray or a rectal suppository.

41. A method of treating an HIV infection in a patient, said method comprising administering to said patient an effective amount of a composition according to any of claims 34-40 to said patient.

42. A method of reducing the likelihood of an HIV infection in a patient at risk said infection, said method comprising administering to said patient an effective amount of a composition according to any of claims 34-40 to said patient.

43. A method of treating a patient with AIDS or ARC comprising administering to said patient a therapeutically effective amount of a composition according to any of claims 34-40.

44. A method of inhibiting HIV integrase in a subject, said method comprising administering to said subject a therapeutically effective amount of a composition according to any of claims 34-40.

45. The method according to any of claims 41-44 wherein said subject is a human.

46. Use of a composition according to any of claims 16-24 and 34-40 in the manufacture of a medicament for the treatment of HIV in a patient.

47. Use of a composition according to any of claims 16-24 and 34-40 in the manufacture of a medicament for reducing the likelihood that a patient will contract an HIV infection.

48. Use of a composition according to any of claims 16-24 and 34-30 in the manufacture of a medicament for treating a patient with AIDS or ARC.

49. Use of a composition according to any of claims 16-24 and 34-40 in the manufacture of a medicament for inhibiting HIV integrase in a subject.

50. Use according to any of claims 46-49 wherein said subject is a human patient.

51. A method of treating an HIV infection in a human host comprising administering to said host in combination, an effective amount of a first compound according to the structure:

wherein the scaffold is independently the 2- and 4-pyridinones identified herein and their regioisomers; R¹ and R² are each independently H, Cj.6 alkyl, Ci-β fluoroalkyl, unsubstituted or substituted C₅.₆ cycloalkyl, Ci^ alkenyl, unsubstituted or substituted phenyl, unsubstituted or substituted benzyl, C₂-₆ alkyl phenyl which phenyl moiety may be optionally substituted, unsubstituted or substituted heteroaryl, C_L6 alkyl substituted with a heteroaryl group which heteroaryl group is optionally substituted, C_1-^ alkyl S(O)R or alkyl (SOa)R where R is alkyl, phenyl or substituted phenyl, C₁^ alkyl CO₂R⁸ where R^a is Ci.₅ alkyl or H, Ci.₆ alkyl COR^a' where R^a is Ci-β alkyl;

R³ and R⁴ are independently selected from H, Ci-6 alkyl, halogen, hydroxyl, unsubstituted or substituted benzyl, or unsubstituted or substituted phenylthio;

R⁵ is CO₂R⁰ or P(O)(OR⁰XOR⁰), where each R° is independently from H and Ci^ alkyl, and pharmaceutically acceptable salts thereof, in combination with at least one additional compound selected from the group consisting of (-)β— Dioxolane-G (DXG); (-)β- Arctigenin (Arctigenin); (-)-Carbovir (-)-C-D4G; (-)-2',3'-Dideoxy-5-fluoro-3'-thiacytidine (FTC); (-)-β-D-2,6-Diaminopurine dioxolane (DAPD); (+)-2¹-Deoxy-3^I-oxa-4'-thiocytidine (dOTC +); (+)-2'-Deoxy-3'-oxa-4'-thio-5-fluorocytidine (dOTFC +); (+/-)-Lobucavir; (R)- 2QuinCOAsnPhe[CHOHCH2]PipCONHtBu; (R)-3,6-Diamino-N-(aminomethyl)hexanamide (Bellenamine); (R)-9-(2-Phosphonylmethoxyproρyl)adenine (Tenofovir); (R)-PMPDAP; (S)- 9-(2-Phosρhonylmethoxypropyl)adenine ((S)-PMPA); PMPA(S); α-APA (Loviride); R87232; R88703; α-APA enantiomer (R90385); α-L-AZT; α-L-Dioxalane-C (α-L-DXC); α-L-FTC;

' α-Monofluoromethyldehydroornithine methyl ester (MFMOME); l,r-Azobisformamide (ADA); l-(ll-Octylamino-10-hydroxyundecyl)-3,7-dimethylxanthine (CT-2576); l-(2',3'-Dideoxy-2^t-fluoro-β-D-threo-pentofuranosyl)cytosine (Ro 31-6840); 1 -(2'-Fluoro-2',3 '-dideoxy-β-D-erythro-pentofuranosyl)thymine (2'FddT); 1 -[(2-Hydroxyethoxy)methyl]-6-(3-methylphenyl)thio)thymine (HEPT-M); 1 -[(2-Hydroxyethoxy)memyl]-6-(phenyltWo)-2-thiomyrnine (HEPT-S); 1 -[(2-Hydroxyethoxy)methyl]-6-(phenylthio)thymine (HEPT); Deoxynojirirnycin (1-Deoxynojirimycin); Amprenavir; Abacavir Succinate(Ziagen); 1- Aminooxyethylamine (AEA); l-Methoxyoxalyl-3,5-dicaffeoylquinic acid (l-MO-3,5- DCQA); lOH-2(Cbz-Tle)3PhPr [14]paracyclophane deriv; 10H-2(Cbz-ValNH)3PhPr [13]metacyclophane deriv.; 10H-2(Cbz-ValNH)3PhPr [13]paracyclophane deriv.; 10H-2(Cbz-ValNH)3PhPr [14]paracyclophane deriv.; 10H-2(Cbz-ValNH)3PhPr [17]paracyclophane deriv.; 12-Deoxyphorbol-13-(3E,5E-decadienoate); 16.alpha.- Bromoepiandrosterone (Epi-Br) or (Inactivin); l-β-D-arabinofuranosyl-5-(2- bromovinyl)uracil (Sorivudine); 2',3'-Didehydro-3'-deoxycytidine (D4C); 2',3'-Dideoxydidehydτoguanosine (D4G); 2',3^l-Didehydro-3'-deoxythymidine (D4T) (Stavudine); 2',3^l-Dideoxy-3^l-fluoro-4-thiothymidine (3'-F-4-Thio-ddT); 2',3^l-Dideoxy-3^l-fluoro-5-bromouridine (FddBrXJ); 2',3'-Dideoxy-3'-fluoro-5-chlorocytidine (3'-F-5-Cl-ddC); 2',3'-Dideoxy-3'-fluoro-5-chloroviridine (935U83) (Raluridine); 2',3'- Dideoxy-5-ethylcytidine (5-Et-ddC); 2^I,3'-Dideoxyadenosine (ddA); 2',3'-Dideoxydidehydroadenosine (d4A); 2',3 -Dideoxyguanosine (ddG); 2',3'-Dideoxy-3'-hydroxymethyl cytidine (3'-Hydroxymethyl-ddC); 2,5^t-Anhydro-3'-azido- 2',3'-dideoxyuridine (AZU-2,5'-anhydro); 2,5^I-Anhydro-3'-azido-3'-deoxythymidine (AZT- 2,5'-anhydro); Z^'diSilySpiroT (TSAO-T); 2',5'diSilySpiroT (TSAO-me^A3T); 2,6-Diamino-2',3^l-dideoxypurine-9-ribofuranoside (ddDAPR)( 2,6- Diamino-ddP); 2,6-Diaminopurine- 2',3'-dideoxydidehydroriboside (ddeDAPR); 2,6- Diaminopurine-3'-fluoro-2',3'-dideoxyriboside (3'-F-ddDAPR); 2-Aminobenzylstatine Valyl Cbz deriv; 2-Glycine amide-5-chlorophenyl 2-pyrryl ketone (GCPK); [2- PyridCH2NCH3CO-Val-NHCH(Bz)]CHOHCHOH (A-77003); 2¹-Azido-2',3'- dideoxyadenosine (2'-N3ddA); 2'-F-dd-ara-A (Lodensine); 2'-FddT ; 2'-N3ddA; 2'-N3ddA (β- D-threo); 2-NaphCOAsnPhe[CHOHCH2]Pro-OtBu; 2-Nitrophenylphenylsulfone (NPPS); 3- (3-Oxo-l-ρropenyl)-3'-azido-3'-deoxythymidine (3-(3-Oxo-l-propenyl)AZT); 3-(3-Oxo-l- propenyl)AZT; L-737,126; 3,5-Dicaffeoylquinic acid (3,5-DCQA); 3'-Azido-3'-deoxy-6- azathymidine; 3'-Azido-2',3^l-dideoxy-5-[(cyanomethyl)oxy]uridine; 3'-Azido-2',3'-dideoxy-5- aminouridine^'-Azido^'jS'-dideoxy-S-aza-ό-deazauridine; S'-Azido^'^'-dideoxy-S- bromouridine; 3'-Azido-2',3'-dideoxy-5-chlorocytidine (3'-Az-5-Cl-ddC); 3'-Azido-2',3'- dideoxy-5-dimethylaminouridine; 3'-Azido-2',3'-dideoxy-5-eth.yluridine; 3'-Azido-2',3'- dideoxy-5-fluorocytidine; 3'-Azido-2',3'-dideoxy-5-fluoro\iridine; 3'-Azido-2',3'-dideoxy-5- hydroxyuridine; 3'-Azido-2',3'-dideoxy-5-iodouridine; 3'-Azido-2',3'-dideoxy-5- methyaminouridine; S'-Azido^'^'-dideoxy-S-methylcytidine; 3^l-Azϊdo-2',3'-dideoxy-5- thiocyanatouridine; 3'-Azido-2'_s3'-dideoxy-5-trifluoromethyluridine; 3'-Azido-2',3'- dideoxycytidine; 3'-Azido-2',3'-dideoxyguanosine; 3'-Azido-2',3'-dideoxy-N4~5- diraethylcytidine; 3^I-Azido-2',3'-dideoxy-N4-OH-5-methylcytidine; 3'-Azido-2^l.3^I- dideoxyuridine (Uravidine); S'-Azido-S'-deoxy-ό-azathymidine; 3-Azido-3'-deoxythymidilyl- (5^t,5⁽)-2',3'-dideoxy-5^l-adenylic acid; 3^>-Azido-3'-deoxythyinidilyl-(5^I _?5^l)-2^t,3'-dideoxy-5^t- adenylic acid, 2-cyanoethyl ester; 3'-Azido-3'-deoxythymidilyl-(5',5¹)-2',3'-dideoxy-5'- inosinic acid (AZT-P-ddl); 3^l-Azido-3^I-deoxythyrnidine-5'-(butylmethoxyvalinyl)phosphate; S'-Azido-S-chloro^'^'-dideoxyuridine; 3'-Deoxythymidine (ddT); g^S'-Fluoro^'.S'-dideoxy- β-D-erythropentafuranosyl)adenine; 3'-Fluoro-2',3'-dideoxy-5-iodouridine (FddIU); 3'-Fluoro-2',3'-dideoxycytidine (3'-FddC); 3'- Fluoro-2',3'-dideoxyguanosine (3'-FddG); 3'-Fluoro-2',3'-dideoxyuridine (3'-FddU); 9-(3'- A2ado-2^3'-dideoxy-p-D-erythropentafuranosyl)adeiiine; 3TC (Lamivudine); 3TC & AZT (Combivir); 4'-Acetoamidophenyl4-guadinobenzoate; 4'-Azido-3'-deoxythymidine; 4'-Azido- 5-chloro-2'-deoxyuridine; 4'-Azido-2'-deoxyadenosine; 4'-Azido-2'-deoxycytidine; 4-Azido- 2'-deoxyguanosine; 4'~Azido-2'-deoxyinosine; 4'-Azido-2'-deoxyuridine; 4'-Azidothymidine; 4'-Cyanothymidine; 4-lvIethyl-5-(pyrazinyl)-3H-l₅2-dithiole-3-thione (Oltipraz); 5'-[(l,4- Dihydro-1 -methyl-3-pyridinylcarbonyl)oxy]-3'-azido-2^l,3 '-deoxythymidine (DP-AZT); 5'- [[(Z)-4-amino-2-butenyl]methylamino]-5'-deoxyadeiiosine (MDL 73811); 5'- Alkylglycosidecarbonate of 3'-azido-3^f-deoxythymidine; 5C13PhS-2IndolCONH2; 5-Fluoro- 2',3'-dideoxycytidine; 5-Methyl-3'-azido-2',3'-dideoxyisocytidine; Celgosivir; 6-Chloro-9- (2,3-dideoxy-β-D-glyceropentoftιranosyl)-9H-purine; 6-Dimethylaminopurine-2',3^t- dideoxyriboside; Ro 24-7429; Ro 5-3335; Tivirapine; 9-(2,3-Dideoxy-β-D-ribofuranosyl)-6- (methylthio)purine; 9-(2^l-Azido-2',3'-dideoxy-B-D-threopentafuranosyl)adenine; C- oxetanocin A; (+-)Lobucavir; A-76890; A-77003; A-77212; A-80987; A-81525; A-83962; A-98881; PNU-104489; Trizivir; Lopinavir; Kaletra; Lopinavir & Ritonavir; Aluviran^® & Norvir; Azodicarbonamide; Adefovir; Adefovir dipivoxil (Preveon®); Nelfinavir; AGl 350 (L Y316957); R-87366; Alpha-lipoic acid; Alovudine (3'-FddT); ALX40-4C; AMD3100 (JM3100); Amdoxovir (APD); Amprenavir phosphate (Fosamprenavir); Ancer 20 (Z-100); Atazanavir (Latazanavir); Atevirdine; Aurintricarboxylic acid; AY 9944; 3'-Azido-5-chloro- 2',3'-dideoxyυridine; AZT; α-L-AZT; O_>O^l-Bis(3'-azido-3'-deoxythymidin-5'- yl)methylphosphonate; Baicalin (TJN-151); Betulinic acid (Mairin); Betulinic acid, 3-O- (3',3'-dimethylsuccinate); Delavirdine (U-90152); U-88204E; Nevirapine; BILA 1906 BS; BILA 2011 BS (Palinavir); BILA 2185 BS; NSC633001; CGP 53820; bis-ValHOEt-N2aza- peptide isostere (CGP 53820 analog); BMS-186318; L-687,908; Brovavir;

BzOCValPhe[diCHOH(RR)]PheValBzOC; BzOCValPhe[diCHOH(SS)]PheValBzOC; C2- Sym Phosphinic amide deriv. (HOECHST AG); NSC675451; Calanolide B; Capravirine (S- 1153); Carbovir; Castanospermine; CGP 61755 (Lasinavir); CGP 64222; CNI-H0294; Emivirine; Conocurvone (NSC650891); Emtricitabine; C-Oxetanocin-G; Indinavir; Curdlan Sulfate; Cyanovirin-N ; SD146; Cyclosporin A; SDZ NIM 811; L^'^'-Didehydro^'^¹- dideoxyadenosine (L-D4A); 2¹,3'-Didehydro-2',3^t-dideoxy-5-fluorocytidine (DD4C); L-2',3'- Didehydro-2',3'-dideoxy-5-fluorocytidine (LD4C); L-2^l,3'-Didehydro-2',3'-dideoxyguanosine (LD4G) ; L-a'^'-Didehydro^'^'-dideoxyinosine (LD4I); DABO; ddl; ddC; DMP-323; DMP- 450; (-)-2'-Deoxy-3'-oxa-4'-thiocytidine; (-)-2'-Deoxy-3'-oxa-4'-thio-5-fluorocytidine ; Pentafuside (Enfuvirtide); Etoposide; Efavirenz; Emtriva; K-12 (fluoroquinoline derivative); Saquinavir; Foscarnet; Phosphonoformic acid; Foscavir; FPMDAP; FPMPA; FPMPG; Gene Expression Modulator 91 (GEM91); Hammerhead anti-gag RNA Ribozyme B; Harziphilone; HBY 097 (Quinoxaline deriv); E-EBU; E-EPSeU; E-EPU; NSC 648400; E-EBU-dM; Zalcitabine; LY326188; Ingenol 3,5,20-triacetate (ITA); Inophyllum B; KNI-272; RD3- 2118; KNI-102; KNI-154; KNI-174; KNI-227; L-685,434; L-689,502; L-697,593; L- 697,639; L-697,661; LY289612; Trovirdine; LY-73497; L-735,524; N-Ethyl-2',3'- dideoxyadenosine; N6-Methyl-2',3^r-dideoxyadenosine; Noa-Asn-Apns-Thz-NH-tBu; Nonoxynol 9; Ritonavir; NSC625487; NSC649324; NSC650898; UC-38; UC-84; P9941 ; Palinavir; Pentosan Sulfate; Elmiron; SP54; PNU- 140690 (Tipranavir); S-2720; Rl 4458; R82150; R82913; R86183; RD4-2138; Resobene; Reyataz; Ribavirin; 7-Chloro-N-methyl-5- (lH-pyrrol-2-yl)-3H-l ,4-benzodiazepin-2-amine; 7-Chloro-5-(2-pyrryl)-3H-l ,4- benzodiazepin-2(H)-one; LY314163; SB-205569; Telinavir; SD-095345SD146; SDZ PRI 053; SPC3; Suramin Sodium; T22; Thalidomide; Thiangazole; Thiazoloisoindol-5-one; U- 104489; U-140690; U-87201E; U-88204E; UC-781; VB-11,328; VX-478; 141 W94; XM-323 and mixtures thereof, further in combination with a pharmaceutically acceptable carrier, additive or excipient.

52. The method according to claim 51 wherein said first compound is

53. A method of treating an HIV infection in a human host comprising administering to said host in combination, an effective amount of a first compound according to the structure:

wherein, the scaffold is independently the 2- and 4-pyridinones identified herein and their regioisomers; R¹ and R² are each independently H, Ci_-6 alkyl, Ci-6 fluoroalkyl, unsubstituted or substituted C₅.₆ cycloalkyl, C ₁-₆ alkenyl, unsubstituted or substituted phenyl, unsubstituted or substituted benzyl, C₂-₆ alkyl phenyl which phenyl moiety may be optionally substituted, unsubstituted or substituted heteroaryl, Cj_-6 alkyl substituted with a heteroaryl group which heteroaryl group is optionally substituted, Q_-6 alkyl S(O)R or alkyl (SC»2)R where R is alkyl, phenyl or substituted phenyl, Ci.₆ alkyl CO₂R³ where R^a is Ci_-6 alkyl or H, Ci_-6 alkyl COR^a' where R^a is C1.6 alkyl;

R³ and R⁴ are independently selected from H, Ci -₆ alkyl, halogen, hydroxy 1, unsubstituted or substituted benzyl, or unsubstituted or substituted phenylthio;

R⁵ is CO₂R⁰ or P(O)(OR^C)(OR^C), where each R^c is independently from H and Ci_-6 alkyl, and pharmaceutically acceptable salts thereof, in combination with at least one additional compound selected from the group consisting of ACV; AK602; AMD070; APV;

ATV; ATZ; AVX754 (apricitabine); AZT; Abacavir, Abacavir / Lamivudine / Zidovudine;

Abacavir sulfate; Abacavir sulfate/Lamivudine; Abacavir/Lamivudine; Abelecet; Acyclovir;

Adefovir dipivoxil; Adriamycin; Agenerase; Aldesleukin; Alovudine; Aluvia; AmBisome; Amdoxovir; Amphocin; Amphotec; Amphotericin B; Ampligen; Amprenavir; Androderm;

Androgel; Apricitabine; Aptivus; Atazanavir; Atripla; Azithromycin; BMS-378806; BMS-

488043; Bactrim; Baraclude; Bevirimat; Biaxin; Brecanavir; BufferGel; C31G; CD4-IgG2;

CS; CV-N; Calanolide A; Calcium hydroxylapatite; Carbopol 974P; Carrageenan;

Carraguard; Cellulose sulfate; Clarithromycin; Combivir; Copegus; Cotrimoxazole; Crixivan; Cyanovirin-N; Cytovene; DAPD; DLV; DS; Darunavir; Delavirdine; Depo-Testosterone;

Dextran sulfate; Didanosine; Diflucan; Doxil; Doxorubicin (liposomal); Dronabinol; EFV;

Efavirenz; Elvucitabine; Emtricitabine; Tenofovir disoproxil fumarate; Emtriva; Enfufirtide;

Entecavir; Epivir; Epoetin alfa; Epogen; Epzicom; Etopophos (phosphate salt); Etoposide; Etravirine; FTC; Fluconazole; Fortovase; Fosamprenavir; Foxivudine tidoxil; Fungizone;

Fuzeon; GS 9137; GSK-873,140 (aplaviroc); GW433908; GW640385 (brecanavir);

Ganciclovir; Globulin, Immune; Growth hormone (human); Hepsera; Hivid; Human growth hormone; IL-2; INH; Immune Globulin Intravenous (Human); Indinavir; Interferon alfa-2; Interleukin-2, recombinant human; Intron A (2b); Invirase; Isoniazid; Itraconazole; KP-1461;

Racivir; Radiesse; Rrebetol; Rescriptor; Retrovir; Reyataz; Ribavirin; Rifabutin; Rifadin; Rifampin; Rimactane; Ritonavir; Roferon-A (2a); Saquinavir; SCH-D (vicriviroc);

Trimetrexate; Trizivir; Truvada (Emtriva and Viread combination); U-90152S (Delaviridine);

UC-781; UK-427,857 (maraviroc); Valcyte; Valganciclovir; Valproic acid; VePesid; Vicriviroc; Videx; Viracept (Tennofovir DF); Viramune; Virazole; Viread; Vitrasert;

Zalcitabine; Zerit; Ziagen; Zidovudine; Zithromax; Zovirax and mixtures thereof, further in combination with a pharmaceutically acceptable carrier, additive or excipient.

54. The method according to claim 53 wherein said first compound is

55. A pharmaceutical composition comprising an effective amount of a compound according to the structure:

in combination with an effective of at least one additional compound selected from the group

(-)β-Dioxolane-G (DXG); (-)β-Arctigenin (Arctigenin); (-)-Carbovir (-)-C-D4G; (-)-2',3'- Dideoxy-5-fluoro-3'-thiacytidϊne (FTC); (-)-β-D-2,6-Diaminopurine dioxolane (DAPD); (+)-

^-Deoxy-S'-oxa-^-thiocytidine (dOTC +); (+)-2^t-Deoxy-3¹-oxa-4'-thio-5-fluorocytidine

(dOTFC +); (+/-)-Lobucavir;

(R)-2QuinCOAsnPhe[CHOHCH2]PipCONHtBu; (R)-3₅6-Diamino-N-

(aminomethyl)hexanamide (Bellenamine); (R)-9-(2-Phosphonylmethoxyproρyl)adenine (Tenofovir); (R)-PMPDAP; (S)-9-(2-Phosphonylmethoxypropyl)adenine ((S)-PMPA);

PMPA(S); α-APA (Lovϊrϊde); R87232; R88703; α-APA enantiomer (R90385); α-L-AZT; α-L-Dioxalane-C (α-L-DXC); α-L-FTC; α-Monofluoromethyldehydroornithine methyl ester (MFMOME); 1 , 1 '-Azobisformamide

(ADA); l-(l l-Octylamino-10-hydroxytmdecyl)-3₅7-dimethylxanthine (CT-2576); 1 -(2^<,3'-Dideoxy-2'-fluoro-β-D-threo-pentoturanosyl)cytosine (Ro 31 -6840);

1 -(2'-Fluoro-2',3 '-dideoxy-β-D-erytriro-pentofuranosyl)mymine (2'FddT);

1 -[(2-Hydroxyethoxy)methyl] -6-(3-methylphenyl)thio)thymine (HEPT-M);

1 -[(2-Hydroxyethoxy)methyl]-6-(phenylthio)-2-thiothymine (HEPT-S); l-[(2-Hydroxyethoxy)methyl]-6-(phenylthio)thymine (HEPT); Deoxynojirimycin (1-Deoxynojirimycin); Amprenavir; Abacavir Succinate(Ziagen); 1-

Aminooxyethylamine (AEA); l-Methoxyoxalyl-3,5-dicaffeoylquinic acid (l-MO-3,5-

DCQA); lOH-2(Cbz-Tle)3PhPr [14]paracyclophane deriv; 10H-2(Cbz-ValNH)3PhPr

[13]metacyclophane deriv.; 10H-2(Cbz-ValNH)3PhPr [13]paracyclophane deriv.;

10H-2(Cbz-ValNH)3PhPr [14]paracyclophane deriv.; 10H-2(Cbz-ValNH)3PhPr [17]paracycloρhane deriv.; 12-Deoxyphorbol-13-(3E,5E-decadienoate); lό.alpha.-

Bromoepiandrosterone (Epi-Br) or (Inactivin); l-β-D-arabinofuranosyl-5-(2- bromovinyl)uracil (Sorivudine); 2',3*-Didehydro-3'-deoxycytidine (D4C); 2',3'-Dideoxydidehydroguanosine (D4G); 2^l,3^I-Didehydro-3^l-deoxythymidine (D4T) (Stavudine); 2',3^I-Dideoxy-3^l-fluoro-4-thiothymidine (3'-F-4-Thio-ddT); 2'₅3'-Dideoxy-3'-fluoro-5-bromouridine (FddBrU); 2',3'-Dideoxy-3'-fluoro-5-chlorocytidine (3'-F-5-Cl-ddC); 2',3^l-Dideoxy-3'-fluoro-5-chlorouridine (935U83) (Raluridine); 2',3'- Dideoxy-5-ethylcytidine (5-Et-ddC); 2',3'-Dideoxyadenosine (ddA); 2^I,3'-Dideoxydidehydroadenosine (d4A); 2',3'-Dideoxyguanosine (ddG); 2',3'-Dideoxy-3'-hydroxymethyl cytidine (3'-Hydroxymethyl-ddC); 2,5'-Anhydro-3'-azido- 2',3'-dideoxyuridine (AZU-2,5'-anhydro); 2,5'-Anhydro-3^!-azido-3'-deoxythymidine (AZT- 2,5'-anhydro); 2',5'diSilySpiroT (TSAO-T); 2',5'diSilySpiroT (TSAO-me^A3T); 2,6-Diamino-2^l ₅3'-dideoxypurine-9-ribofuranoside (ddDAPR)( 2,6- Diamino-ddP); 2,6-Diaminopurine- 2',3'-dideoxydidehydroriboside (ddeDAPR); 2,6- Diaminopurine-3'-fluoro-2^l,3^l-dideoxyriboside (3'-F-ddDAPR); 2-Aminobenzylstatine Valyl Cbz deriv; 2-Glycine amide-5-chlorophenyl 2-pyrryl ketone (GCPK); [2- PyridCH2NCH3CO-Val-NHCH(Bz)]CHOHCHOH (A-77003); 2'-Azido-2',3^I- dideoxyadenosine (2'-N3ddA); 2'-F-dd-ara-A (Lodensine); 2'-FddT ; 2'-N3ddA; 2'-N3ddA (β- D-threo); 2-NaphCOAsnPhe[CHOHCH2]Pro-OtBu; 2-Nitrophenylphenylsulfone (NPPS); 3- (3-Oxo- 1 -propenyl)-3'-azido-3'-deoxythymidine (3-(3-Oxo-l -propeny I)AZT); 3-(3-Oxo- 1 - propenyl)AZT; L-737,126; 3,5-Dicaffeoylquinic acid (3,5-DCQA); 3'-Azido-3'-deoxy-6- azathymidine; S'-Azido^'.S'-dideoxy-S-Kcyanomethy^oxyjuridine; 3'-Azido-2',3'-dideoxy-5- aminouridine; S'-Azido^'.S'-dideoxy-S-aza-ό-deazauridine; 3'-Azido-2',3'-dideoxy-5- bromouridine; 3'-Azido-2',3'-dideoxy-5-chlorocytidine (3'-Az-5-Cl-ddC); 3'-Azido-2',3'- dideoxy-5-dimethylaminouridine; S'-Azido^'.S'-dideoxy-S-ethyluridine; 3'-Azido-2',3'- dideoxy-5-fluorocytidine; S'-Azido^'.S'-dideoxy-S-fluorouridine; 3'-Azido-2',3'-dideoxy-5- hydroxyuridine; 3'-Azido-2',3'-dideoxy-5-iodouridine; 3'-Azido-2',3'-dideoxy-5- methyaminouridine; S'-Azido^'^'-dideoxy-S-methylcytidine; 3'-Azido-2',3'-dideoxy-5- thiocyanatouridine; 3'-Azido-2',3'-dideoxy-5-trifluoromethyluridine; 3'-Azido-2',3'- dideoxycytidine; 3'-Azido-2',3'-dideoxyguanosine; 3^?-Azido-2',3'-dideoxy-N4~5- dimethylcytidine; 3^t-Azido-2',3^l-dideoxy-N4-OH-5-methylcytidine; 3'-Azido-2^l,3^r- dideoxyuridine (Uravidine); 3'-Azido-3'-deoxy-6-azathyinidine; 3-Azido-3'-deoxythymidilyl- (S'^O^'^'-dideoxy-S'-adenylic acid; 3'-Azido-3^I-deoxythymidilyl-(5¹,5')-2¹ ₉3^t-dideoxy-5¹- adenylic acid, 2-cyanoethyl ester; 3'-Azido-3'-deoxythymidilyl-(5'₅5^l)-2',3'-dideoxy-5^l- inosinic acid (AZT-P-ddl); 3'-Azido-3'-deoxythymidine-5'-(butylmethoxyvalinyl)phosphate; 3'-Azido-5-chloro-2^l,3'-dideoxyuridine; 3'-Deoxythymidine (ddT); 9-(3'-Fluoro-2',3'-dideoxy- β-D-erythropentafuranosyl)adenine;

S'-Fluoro^'^'-dideoxy-S-iodouridine (FddIU); 3'-Fluoro-2',3'-dideoxycytidine (3'-FddC); 3¹- Fluoro-2',3'-dideoxyguanosine (3'-FddG); S'-Fluoro^'.S'-dideoxvuridine (3'-FddU); 9-(3'- Azido-2',3'-dideoxy-p-D-erythropentafuranosyl)adenine; 3TC (Lamivudine); 3TC & AZT (Combivir); 4'-Acetoamidophenyl4-guadinobenzoate; 4'-Azido-3'-deoxythymidine; 4'-Azido- 5-chloro-2'-deoxyuridine; 4'-Azido-2'-deoxyadenosine; 4'-Azido-2'-deoxycytidine; 4'-Azido- 2'-deoxyguanosine; 4'-Azido-2'-deoxyinosine; 4'-Azido-2'-deoxyuridine; 4'-Azidothyinidine; 4'-Cyanothymidine; 4-Methyl-5-φyrazinyl)-3H-l,2-dittøole-3-thione (Oltipraz); 5'-[(l,4- Dihydro-l-methyl-3-pyridinylcarbonyl)oxy]-3'-azido-2^3'-deoxythyinidine (DP-AZT); 5'- [[(Z)-4-amino-2-butenyl]methylamino]-5'-deoxyadenosine (MDL 73811); 5'- Alkylglycosidecarbonate of 3'-azido-3'-deoxythymidine; 5C13PhS-2IndolCONH2; 5-Fluoro- 2',3'-dideoxycytidine; 5-Methyl-3'-azido-2',3^r-dideoxyisocytidine; Celgosivir; 6-Chloro-9- (23-dideoxy-β-D-glyceropentofuranosyl)-9H-pviτine; 6-Dimethylaminopurine-2',3'- dideoxyriboside; Ro 24-7429; Ro 5-3335; Tivirapine; 9-(2,3-Dideoxy-β-D-ribofuranosyl)-6- (methylthio)purine; 9-(2'-Azido-2',3'-dideoxy-B-D-threopentafuranosyl)adenine; C- oxetanocin A; (+-)Lobucavir; A-76890; A-77003; A-77212; A-80987; A-81525; A-83962; A-98881; PNU- 104489; Trizivir; Lopinavir; Kaletra; Lopinavir & Ritonavir; Aluviran^® & Norvir; Azodicarbonamide; Adefovir; Adefovir dipivoxil (Preveon®); Nelfinavir; AG 1350 (LY316957); R-87366; Alpha-lipoic acid; Alovudine (3'-FddT); ALX40-4C; AMD3100

(JM3100); Amdoxovir (APD); Amprenavir phosphate (Fosamprenavir); Ancer 20 (Z-100); Atazanavir (Latazanavir); Atevirdine; Aurintricarboxylic acid; AY 9944; 3'-Azido-5-chloro- 2',3'-dideoxyuridine; AZT; α-L-AZT; O,O'-Bis(3'-azido-3^f-deoxythymidin-5'- yl)methylphosphonate; Baicalin (TJN-151); Betulinic acid (Mairin); Betulinic acid, 3-O- (3',3'-dimethylsuccinate); Delavirdine (U-90152); U-88204E; Nevirapine; BILA 1906 BS; BILA 2011 BS (Palinavir); BILA 2185 BS; NSC633001; CGP 53820; bis-ValHOEt-N2aza- peptide isostere (CGP 53820 analog); BMS-186318; L-687,908; Brovavir; BzOCValPhe[diCHOH(RR)]PheValBzOC; BzOCValPhe[diCHOH(SS)]PheValBzOC; C2- Sym Phosphinic amide deriv. (HOECHST AG); NSC675451 ; Calanolide B; Capravirine (S- 1153); Carbovir; Castanospermine; CGP 61755 (Lasinavir); CGP 64222; CNI-H0294;

Emivirine; Conocurvone (NSC650891); Emtricitabine; C-Oxetanocin-G; Indinavir; Curdlan Sulfate; Cyanovirin-N ; SD146; Cyclosporin A; SDZ NIM 811; L-2',3^I-Didehydro-2^I,3¹- dideoxyadenosine (L-D4A); 2^t,3'-Didehydro-2',3'-dideoxy-5-fluorocytidine (DD4C); L-2',3'- Didehydro-2',3'-dideoxy-5-fluorocytidine (LD4C); L-2^l,3'-Didehydro-2^I,3'-dideoxyguanosine (LD4G) ; L^'.S'-Dϊdehydro^'^'-dideoxyinosine (LD4I); DABO; ddl; ddC; DMP-323; DMP- 450; (-)-2'-Deoxy-3'-oxa-4'-thiocytidine; (-)-2'-Deoxy-3'-oxa-4'-thio-5-fluorocytidine ; Pentafuside (Enfuvirtide); Etoposide; Efavirenz; Emtriva; K-12 (fluoroquinoline derivative); Saquinavir; Foscarnet; Phosphonoformic acid; Foscavir; FPMDAP; FPMPA; FPMPG; Gene Expression Modulator 91 (GEM91); Hammerhead anti-gag RNA Ribozyme B; Harziphilone; HBY 097 (Quinoxaline deriv); E-EBU; E-EPSeU; E-EPU; NSC 648400; E-EBU-dM; Zalcitabine; LY326188; Ingenol 3,5,20-triacetate (ITA); Inophyllum B; KNI-272; RD3- 2118; KNI-102; KNI-154; KNI-174; KNI-227; L-685,434; L-689,502; L-697,593; L- 697,639; L-697,661; LY289612; Trovirdine; LY-73497; L-735,524; N-Ethyl-2',3¹- dideoxyadenosine; N6-Methyl-2',3'-dideoxyadenosine; Noa-Asn-Apns-Thz-NH-tBu; Nonoxynol 9; Ritonavir; NSC625487; NSC649324; NSC650898; UC-38; UC-84; P9941; Palinavir; Pentosan Sulfate; Elmiron; SP54; PNU-140690 (Tipranavir); S-2720; R14458; R82150; R82913; R86183; RD4-2138; Resobene; Reyataz; Ribavirin; 7-Chloro-N-methyl-5- (lH-pyiτol-2-yl)-3H-l,4-benzodiazepin-2-amine; 7-Chloro-5-(2-pyrryl)-3H-l,4- benzodiazepin-2(H)-one; LY314163; SB-205569; Telinavir; SD-095345SD146; SDZ PRI 053; SPC3; Suramin Sodium; T22; Thalidomide; Thiangazole; Thiazoloisoindol-5-one; U- 104489; U-140690; U-87201E; U-88204E; UC-781; VB-11,328; VX-478; 141 W94; XM-323 and mixtures thereof, further in combination with a pharmaceutically acceptable carrier, additive or excipient.

56. A pharmaceutical composition comprising an effective amount of a compound according to the structure:

in combination with an effective of at least one additional compound selected from the group ACV; AK602; AMD070; APV; ATV; ATZ; AVX754 (apricitabine); AZT; Abacavir; Abacavir / Lamivudine / Zidovudine; Abacavir sulfate; Abacavir sulfate/Lamivudine; Abacavir/Lamivudine; Abelecet; Acyclovir; Adefovir dipivoxil; Adriamycin; Agenerase;

Aldesleukin; Alovudine; Aluvia; AmBisome; Amdoxovir; Amphocin; Amphotec;

Amphotericin B; Ampligen; Amprenavir; Androdeπn; Aπdrogel; Apricitabine; Aptivus;

Atazanavir; Atripla; Azithromycin; BMS-378806; BMS-488043; Bactrim; Baraclude; Bevirimat; Biaxin; Brecanavir; BufferGel; C31G; CD4-IgG2; CS; CV-N; Calanolide A;

Calcium hydroxylapatite; Carbopol 974P; Carrageenan; Carraguard; Cellulose sulfate;

Clarithromycin; Combivir; Copegus; Cotrimoxazole; Crixivan; Cyanovirin-N; Cytovene;

DAPD; DLV; DS; Darunavir; Delavirdine; Depo-Testosterone; Dextran sulfate; Didanosine;

Diflucan; Doxil; Doxorubicin (liposomal); Dronabinol; EFV; Efavirenz; Elvucitabine; Emtricitabine; Tenofovir disoproxil fumarate; Emtriva; Enfufirtide; Entecavir; Epivir;

Epoetin alfa; Epogen; Epzicom; Etopophos (phosphate salt); Etoposide; Etravirine; FTC;

Fluconazole; Fortovase; Fosamprenavir; Foxivudine tidoxil; Fungizone; Fuzeon; GS 9137;

GSK-873,140 (aplaviroc); GW433908; GW640385 (brecanavir); Ganciclovir; Globulin,

Immune; Growth hormone (human); Hepsera; Hivid; Human growth hormone; IL-2; INH; Immune Globulin Intravenous (Human); Indinavir; Interferon alfa-2; Interleukin-2, recombinant human; Intron A (2b); Invirase; Isoniazid; Itraconazole; KP-1461;

Lamivudine/Zidovudine; Lexiva; Lopinavir/Ritonavir; MK-0518; Nebupent; Nelfinavir; •

Rifampin; Rimactane; Ritonavir; Roferon-A (2a); Saquinavir; SCH-D (vicriviroc);